

# **HEALTH QUARTERLY STATEMENT**

AS OF MARCH 31, 2023 OF THE CONDITION AND AFFAIRS OF THE

# Martin's Point Generations Advantage, Inc.

NAIC		000 NAIC Co	mpany Code	15850 Employer	's ID Number47	-4682941
Organized under the Laws of	(Current) (F Main	,	, Sta	te of Domicile or Port o	f Entry	ME
Country of Domicile		Unit	ed States of An	nerica		
Licensed as business type:		Health N	Maintenance Or	ganization		
Is HMO Federally Qualified? Ye	s[X]No[]					
Incorporated/Organized	07/31/2015		C	ommenced Business		01/01/2016
Statutory Home Office	331 Veranda S	treet	,		Portland, ME, US	04103
	(Street and Nur	nber)		(City	or Town, State, Counti	ry and Zip Code)
Main Administrative Office			31 Veranda Str			
ŗ	Portland, ME, US 04103	,	Street and Num	per)	207-774-580	1
(City or To	wn, State, Country and Zip Co				(Area Code) (Telephor	ne Number)
Mail Address	PO Box 9746				Portland, ME, US 04	
	(Street and Number or P.C	). Box)		(City	or Town, State, Countr	ry and Zip Code)
Primary Location of Books and R	ecords	/0	PO Box 9746			
Por	tland, ME, US 04104-5040	(0	,	Jei)	207-774-580	1
(City or To	wn, State, Country and Zip Co	ode)			(Area Code) (Telephor	ne Number)
Internet Website Address		W	ww.martinspoin	t.org		
Statutory Statement Contact		cKean Evans		,	207-774	
warr	ا) en.evans@martinspoint.org	Name)			(Area Code) (Tele 207-253-622	•
	(E-mail Address)				(FAX Numbe	
			OFFICERS			
President						athryn Jean Rand
Chair	Edward Stewart	McKersie		Treasurer	Brac	dford Adams Hunter
David Emery Curr	er, Secretary	Amanda LeAnr	OTHER a Jackson, Chi	ef Financial Officer	Bernadette Ma	rie Di Re, Chief Operating Officer
Barbara Elizabeth Ronald Fitzjohn		Ge	TORS OR TR orge John Isha n Edward Fitzsi	m ,MD		en Elizabeth Morrow ,MD ephen Paul deCastro
Konalu Fitzjonin	UIXOII ,IIIO	JUII	II EUWAIU FILZSI	IIIIIons		epiteri Faui deCasilo
State of	Maine	— ss:				
County of	Cumberland					
all of the herein described asset statement, together with related condition and affairs of the said r in accordance with the NAIC An rules or regulations require diffrespectively. Furthermore, the s	s were the absolute property exhibits, schedules and explar aporting entity as of the reportural Statement Instructions are prences in reporting not relactope of this attestation by the	of the said reporti ations therein con ing period stated a nd Accounting Pra ted to accounting described officers	ng entity, free tained, annexed above, and of its ctices and Proof practices and also includes	and clear from any lied or referred to, is a full is income and deduction dedures manual except I procedures, according the related corresponding	ns or claims thereon, I and true statement of his therefrom for the pe t to the extent that: (1) hig to the best of thei ling electronic filing wit	t on the reporting period stated above, except as herein stated, and that this all the assets and liabilities and of the riod ended, and have been completed state law may differ; or, (2) that state ir information, knowledge and belief, the NAIC, when required, that is an rious regulators in lieu of or in addition
Paul Francis Kasuba President & CEO Subscribed and sworn to before r day of	)	Ch				Yes [X] No []
				2. Date filed		

3. Number of pages attached......

# **ASSETS**

•	AS	SETS			
	-	1	Current Statement Date	3	4 December 31
		Assets	Nonadmitted Assets	Net Admitted Assets	Prior Year Net Admitted Assets
1.	Bonds			(Cols. 1 - 2) 22, 197, 784	
		22, 137, 704		22, 197,704	40,737,411
۷.	Stocks: 2.1 Preferred stocks			0	0
	2.2 Common stocks			32,291,205	
2		32,291,203			30 , 134 , 039
3.	Mortgage loans on real estate: 3.1 First liens			0	0
	3.2 Other than first liens.			0	0
4.	Real estate:				
٦.	4.1 Properties occupied by the company (less \$				
	encumbrances)			0	0
	4.2 Properties held for the production of income (less				
	\$ encumbrances)			0	0
	4.3 Properties held for sale (less \$				
	encumbrances)			0	0
5	Cash (\$110,520,334 ), cash equivalents				
Э.	(\$4,275,414 ) and short-term				
	investments (\$	11/ 705 7/0		114 705 740	41 004 900
6	Contract loans (including \$ premium notes)			0	
	Derivatives			0	
7. 8.	Other invested assets				
o. 9.	Receivables for securities				
9. 10.	Securities lending reinvested collateral assets				
11.	Aggregate write-ins for invested assets				
12.	Subtotals, cash and invested assets (Lines 1 to 11)			184,670,503	
	Title plants less \$ charged off (for Title insurers	104,070,000		104,070,000	
10.	only)			0	0
14.	Investment income due and accrued			114,529	
15.	Premiums and considerations:	,		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,,,,,
	15.1 Uncollected premiums and agents' balances in the course of collection	596.380	524.254	72 . 126	
	15.2 Deferred premiums, agents' balances and installments booked but				,
	deferred and not yet due (including \$				
	earned but unbilled premiums)			0	0
	15.3 Accrued retrospective premiums (\$				
	contracts subject to redetermination (\$2,670,789 )	67,985,315		67,985,315	44,589,500
16.	Reinsurance:			, ,	
	16.1 Amounts recoverable from reinsurers			0	0
	16.2 Funds held by or deposited with reinsured companies			0	0
	16.3 Other amounts receivable under reinsurance contracts			0	0
17.	Amounts receivable relating to uninsured plans				
18.1	Current federal and foreign income tax recoverable and interest thereon			0	0
18.2	Net deferred tax asset			0	0
19.	Guaranty funds receivable or on deposit				
20.	Electronic data processing equipment and software			0	0
21.	Furniture and equipment, including health care delivery assets				
	(\$				0
22.	Net adjustment in assets and liabilities due to foreign exchange rates				0
23.	Receivables from parent, subsidiaries and affiliates				
24.	Health care (\$ 15,970,263 ) and other amounts receivable			15,971,129	
25.	Aggregate write-ins for other than invested assets	0	0	0	0
26.	Total assets excluding Separate Accounts, Segregated Accounts and	000 054 700	4F 000 FF0	070 004 000	105 100 007
07	Protected Cell Accounts (Lines 12 to 25)	289,201,783	15,920,550	2/3,331,233	195, 190,287
21.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts			0	0
28.	Total (Lines 26 and 27)	289,251,783	15,920,550	273,331,233	195, 190, 287
	DETAILS OF WRITE-INS				
1101.				0	0
1102.				0	0
1103.				0	0
1198.	Summary of remaining write-ins for Line 11 from overflow page	0	0	0	0
1199.	Totals (Lines 1101 through 1103 plus 1198)(Line 11 above)	0	0	0	0
2501.				0	0
2502.					0
2503.				0	0
2598.	Summary of remaining write-ins for Line 25 from overflow page			0	0
2599.	Totals (Lines 2501 through 2503 plus 2598)(Line 25 above)	0	0		0

# LIABILITIES, CAPITAL AND SURPLUS

	LIADILITIES, CAP	1171271112	Current Period		Prior Year
		1	2	3	4
		Covered	Uncovered	Total	Total
1.	Claims unpaid (less \$ reinsurance ceded)	78,658,915		78,658,915	78,886,325
2.	Accrued medical incentive pool and bonus amounts				2,601,233
3.	Unpaid claims adjustment expenses			1,836,327	1,902,629
		1,000,027		1,000,021	1,002,020
4.	Aggregate health policy reserves, including the liability of				
	\$1,094,929 for medical loss ratio rebate per the Public				
	Health Service Act			1,094,929	, ,
5.	Aggregate life policy reserves			0	0
6.	Property/casualty unearned premium reserve			0	0
7.	Aggregate health claim reserves			0	0
8.	Premiums received in advance				1 243 060
9.	General expenses due or accrued				
	•				
10.1	0 1 7				
	(including \$ on realized gains (losses))				0
10.2	Net deferred tax liability			0	0
11.	Ceded reinsurance premiums payable			0	0
12.	Amounts withheld or retained for the account of others			0	0
13.	Remittances and items not allocated				
	Borrowed money (including \$ current) and			v	
14.	,				
	interest thereon \$ (including				
	\$ current)				
15.	Amounts due to parent, subsidiaries and affiliates	3,914,636		3,914,636	0
16.	Derivatives			0	0
17.	Payable for securities			0	0
18.	Payable for securities lending				
19.	Funds held under reinsurance treaties (with \$			v	
19.	•				
	authorized reinsurers, \$ unauthorized				
	reinsurers and \$ certified reinsurers)			0	0
20.	Reinsurance in unauthorized and certified (\$				
	companies			0	0
21.	Net adjustments in assets and liabilities due to foreign exchange rates			0	0
22.	Liability for amounts held under uninsured plans				
23.	Aggregate write-ins for other liabilities (including \$				
23.		00 405 000	0	00 405 000	00 000 000
	current)			22,485,000	
24.	Total liabilities (Lines 1 to 23)				
25.	Aggregate write-ins for special surplus funds	XXX	XXX	0	0
26.	Common capital stock	XXX	XXX		
27.	Preferred capital stock	XXX	XXX		
28.	Gross paid in and contributed surplus				
29.	Surplus notes				
	Aggregate write-ins for other than special surplus funds				0
30.					
31.	Unassigned funds (surplus)	XXX	XXX	(86,513,585)	(98,950,712)
32.	Less treasury stock, at cost:				
	32.1 shares common (value included in Line 26				
	\$	XXX	XXX		
	32.2 shares preferred (value included in Line 27				
	\$)	YYY	YYY		
22	Total capital and surplus (Lines 25 to 31 minus Line 32)				
33.					
34.	Total liabilities, capital and surplus (Lines 24 and 33)	XXX	XXX	273,331,231	195,190,289
	DETAILS OF WRITE-INS				
2301.	Potential settlement	22,485,000		22,485,000	20,000,000
2302.				0	0
2303.					0
	Summary of remaining write-ins for Line 23 from overflow page				
2398.					0
2399.	Totals (Lines 2301 through 2303 plus 2398)(Line 23 above)		0	22,485,000	20,000,000
2501.					
2502.		XXX	XXX		0
2503.		XXX	XXX		0
2598.	Summary of remaining write-ins for Line 25 from overflow page				
2599.		XXX	XXX	0	0
	<u> </u>				
3001.					
3002.					
3003.					
3098.	Summary of remaining write-ins for Line 30 from overflow page	xxx	XXX	0	0
3099.	Totals (Lines 3001 through 3003 plus 3098)(Line 30 above)	XXX	XXX	0	0
5555.	. State (Entree occit an occident occident occident occident occident	///\	///\	<u> </u>	<u> </u>

# STATEMENT OF REVENUE AND EXPENSES

			rent Year		Prior Year	Prior Year Ended
		1	o Date	2 Tatal	To Date 3	December 31 4
1.	Member Months	Uncovered		Total208,379	Total 192,260	Total 789,627
2.	Net premium income ( including \$ non-health			200,070	102,200	
	premium income)	XXX		179 , 770 , 774	160,665,833	657,548,288
3.	Change in unearned premium reserves and reserve for rate credits					
4.	Fee-for-service (net of \$ medical expenses)					
5.	Risk revenue					
6.	Aggregate write-ins for other health care related revenues	XXX		0	0	0
7.	Aggregate write-ins for other non-health revenues					
8.	Total revenues (Lines 2 to 7)	XXX		179 , 770 , 774	160,665,833	657,548,288
	Hospital and Medical:					
9.	Hospital/medical benefits			137,594,532	133,788,973	530,254,611
10.	Other professional services					
11.	Outside referrals					
12.	Emergency room and out-of-area					
13.	Prescription drugs					
14.	Aggregate write-ins for other hospital and medical					0
15.	Incentive pool, withhold adjustments and bonus amounts					4,423,286
16.	Subtotal (Lines 9 to 15)		٠	152,235,59/	153, 180,91/	590,418,31/
4-	Less:		1			
17.	Net reinsurance recoveries					
18. 19.	Non-health claims (net)					
20.	Claims adjustment expenses, including \$					
20.	containment expenses			4 797 821	4 452 715	20 560 092
21.	General administrative expenses					
22.	Increase in reserves for life and accident and health contracts			17,007,000	11,024,000	
	(including \$ increase in reserves for life only)				2 482 361	(5 698 680)
23.	Total underwriting deductions (Lines 18 through 22)					
24.	Net underwriting gain or (loss) (Lines 8 minus 23)					
25.	Net investment income earned					
26.	Net realized capital gains (losses) less capital gains tax of					
	\$			274,634	(14,140)	(453, 124)
27.	Net investment gains (losses) (Lines 25 plus 26)		0	755,369	147,484	1,128,145
28.	Net gain or (loss) from agents' or premium balances charged off [(amount					
	recovered \$ )					
	(amount charged off \$)])]					
29.	Aggregate write-ins for other income or expenses		0	0	0	(20,000,000)
30.	Net income or (loss) after capital gains tax and before all other federal income taxes (Lines 24 plus 27 plus 28 plus 29)	<b>VVV</b>		6 305 332	(11 127 642)	(17 520 061)
31.	Federal and foreign income taxes incurred			0,090,002	(11, 127,042)	(17,329,001)
32.	Net income (loss) (Lines 30 minus 31)	XXX		6,395,332	(11, 127, 642)	(17,529,061)
32.	DETAILS OF WRITE-INS	<b>XXX</b>		0,000,002	(11, 121, 042)	(17,020,001)
0601.	DETAILS OF WATE-ING	***				0
0602.					0	0
0603.						0
0698.	Summary of remaining write-ins for Line 6 from overflow page			0	۰ ا	
0699.	Totals (Lines 0601 through 0603 plus 0698)(Line 6 above)	XXX		0	۰ ا	٥
0701.	, , , , ,			v	O O	0
		XXX				0
0702.		XXX			0	0
0703.	Cummany of samplining write inc for Line 7 from quadray ages				0	0
0798.	Summary of remaining write-ins for Line 7 from overflow page			0		 ^
0799. 1401.	Totals (Lines 0701 through 0703 plus 0798)(Line 7 above)	XXX	+	U	0	0
			.			0
1402.					0	0
1403					0	0
1498.	Summary of remaining write-ins for Line 14 from overflow page			0	0	0
1499.	Totals (Lines 1401 through 1403 plus 1498)(Line 14 above)		0	0	0	(00 000 000
2901.	Potential settlement					(20,000,000)
2902.						0
2903					0	0
2998.	Summary of remaining write-ins for Line 29 from overflow page			0	0	0
2999.	Totals (Lines 2901 through 2903 plus 2998)(Line 29 above)		0	0	0	(20,000,000)

## **STATEMENT OF REVENUE AND EXPENSES (Continued)**

	STATEMENT OF REVENUE AND EX	1	2	3
		Current Year to Date	Prior Year to Date	Prior Year Ended December 31
	CAPITAL AND SURPLUS ACCOUNT			
33.	Capital and surplus prior reporting year	86,149,286	78,764,756	78,764,756
34.	Net income or (loss) from Line 32	6,395,332	(11, 127, 642)	(17,529,061)
35.	Change in valuation basis of aggregate policy and claim reserves			
36.	Change in net unrealized capital gains (losses) less capital gains tax of \$	2,157,380	(1,634,380)	(4,971,921)
37.	Change in net unrealized foreign exchange capital gain or (loss)			
38.	Change in net deferred income tax			
39.	Change in nonadmitted assets	3,884,416	3,361,408	4,885,512
40	Change in unauthorized and certified reinsurance	0	0	0
41.	Change in treasury stock			
42.	Change in surplus notes		0	
43.	Cumulative effect of changes in accounting principles			
44.	Capital Changes:			
44.			0	0
	44.1 Paid in			
	44.2 Transferred from surplus (Stock Dividend)			
	44.3 Transferred to surplus			
45.	Surplus adjustments:			
	45.1 Paid in	0	0	25,000,000
	45.2 Transferred to capital (Stock Dividend)			
	45.3 Transferred from capital			
46.	Dividends to stockholders			
47.	Aggregate write-ins for gains or (losses) in surplus	0	0	0
48.	Net change in capital & surplus (Lines 34 to 47)	12,437,128	(9,400,614)	7,384,530
49.	Capital and surplus end of reporting period (Line 33 plus 48)	98,586,414	69,364,142	86,149,286
	DETAILS OF WRITE-INS			
4701.				0
4702.			0	0
4703.			0	0
4798.	Summary of remaining write-ins for Line 47 from overflow page		0	0
		0	0	0
4799.	Totals (Lines 4701 through 4703 plus 4798)(Line 47 above)	U	U	Ü

## **CASH FLOW**

	CASH FLOW			
		1 Current Year To Date	2 Prior Year To Date	3 Prior Year Ended December 31
	Cash from Operations			
1.	Premiums collected net of reinsurance	215 , 734 , 452	148,643,908	638,018,870
2.	Net investment income	476,276	252,452	1,607,004
3.	Miscellaneous income	(1,410,514)	(13,640)	4,897,059
4.	Total (Lines 1 to 3)	214,800,214	148,882,720	644,522,933
5.	Benefit and loss related payments	154,897,395	146,967,162	582,811,084
6.	Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts			
7.	Commissions, expenses paid and aggregate write-ins for deductions	16,137,678	13,317,631	
8.	Dividends paid to policyholders			
9.	Federal and foreign income taxes paid (recovered) net of \$			•
	gains (losses)	0	0	0
10.	Total (Lines 5 through 9)	171,035,073	160,284,793	672,270,474
11.	Net cash from operations (Line 4 minus Line 10)	43,765,142	(11,402,073)	(27,747,541)
	Cash from Investments			
12.	Proceeds from investments sold, matured or repaid:			
	12.1 Bonds	18,881,174	20,179,863	29,444,096
	12.2 Stocks			
	12.3 Mortgage loans	0	0	0
	12.4 Real estate	0	0	0
	12.5 Other invested assets			
	12.6 Net gains or (losses) on cash, cash equivalents and short-term investments	0	0	0
	12.7 Miscellaneous proceeds	0	0	0
	12.8 Total investment proceeds (Lines 12.1 to 12.7)	18,881,174	20 , 179 , 863	29,444,096
13.	Cost of investments acquired (long-term only):			
	13.1 Bonds	5,567	233,611	29,473,540
	13.2 Stocks	0	0	7,396,942
	13.3 Mortgage loans	0	0	0
	13.4 Real estate	0	0	0
	13.5 Other invested assets	0	0	0
	13.6 Miscellaneous applications	15,355,944	155	29,818
	13.7 Total investments acquired (Lines 13.1 to 13.6)	15,361,511	233,766	36,900,300
14.	Net increase (or decrease) in contract loans and premium notes	0	0	0
15.	Net cash from investments (Line 12.8 minus Line 13.7 and Line 14)	3,519,663	19,946,097	(7,456,205)
	Cash from Financing and Miscellaneous Sources			
16.	Cash provided (applied):			
	16.1 Surplus notes, capital notes	0	0	0
	16.2 Capital and paid in surplus, less treasury stock	0	0	25,000,000
	16.3 Borrowed funds	0	0	0
	16.4 Net deposits on deposit-type contracts and other insurance liabilities	0	0	0
	16.5 Dividends to stockholders	0	0	0
	16.6 Other cash provided (applied)	26,416,144	15,368,659	11,456,618
17.	Net cash from financing and miscellaneous sources (Line 16.1 through Line 16.4 minus Line 16.5 plus Line 16.6)	26,416,144	15,368,659	36,456,618
	DECONCILIATION OF CASH, CASH EQUIVALENTS AND SHOOT TEDM INVESTMENTS			
10	RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS  Not change in each cash equivalents and short term investments (Line 11, plus Lines 15 and 17)	73,700,948	23 012 602	1 252 072
18.	, , ,	13,700,940	23,812,002	1,252,873
19.	Cash, cash equivalents and short-term investments:	41 004 700	20 044 007	20 044 007
	19.1 Beginning of year			
	19.2 End of period (Line 18 plus Line 19.1)	114,795,748	63,754,609	41,094,799

Note: Supplemental disclosures of cash flow information for non-cash transactions:		

## **EXHIBIT OF PREMIUMS, ENROLLMENT AND UTILIZATION**

		<u></u>	<u> </u>		<u>,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,</u>			<u> </u>	<u> </u>	<u> </u>				
	1	Comprel (Hospital 8	nensive Medical)	4	5	6	7	8	9	10	11	12	13	14
	Total	2 Individual	3 Group	Medicare Supplement	Vision Only	Dental Only	Federal Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Credit A&H	Disability Income	Long-Term Care	Other Health	Other Non-Health
Total Members at end of:					•	•								
1. Prior Year	68,219	0	0	0	0	0	0	68,219	0	0	0	0	0	
2. First Quarter								69,763						
Second Quarter	0													
4. Third Quarter														
5. Current Year	0													
6. Current Year Member Months	208,379							208,379						
Total Member Ambulatory Encounters for Period:														
7 Physician	253,971							253,971						
8. Non-Physician	167,815							167,815						
9. Total	421,786	0	0	0	0	0	0	421,786	0	0	0	0	0	(
10. Hospital Patient Days Incurred	5,405							5,405						
11. Number of Inpatient Admissions	1,083							1,083						
12. Health Premiums Written (a)	179,770,774							179,770,774						
13. Life Premiums Direct	0				•									
14. Property/Casualty Premiums Written	0													
15. Health Premiums Earned	179,770,774							179,770,774						
16. Property/Casualty Premiums Earned	0													
Amount Paid for Provision of Health     Care Services	152,715,205							152,715,205						
18. Amount Incurred for Provision of Health Care Services	152,235,597							152,235,597						

<sup>(</sup>a) For health premiums written: amount of Medicare Title XVIII exempt from state taxes or fees \$

# CLAIMS UNPAID AND INCENTIVE POOL, WITHHOLD AND BONUS (Reported and Unreported)

Aging Analysis of Unpaid	Claims					
1	2	3	4	5	6	7
Account	1 - 30 Days	31 - 60 Days	61 - 90 Days	91 - 120 Days	Over 120 Days	Total
Claims Unpaid (Reported)		•	•			
,						
0299999 Aggregate accounts not individually listed-uncovered						0
0399999 Aggregate accounts not individually listed-covered	9,936,584					9,936,584
0499999 Subtotals	9,936,584	0	0	0	0	9,936,584
0599999 Unreported claims and other claim reserves						
0699999 Total amounts withheld						68,722,331
0799999 Total claims unpaid						78,658,915
0899999 Accrued medical incentive pool and bonus amounts						2,349,036
······ ··· ··· ··· ·· ·· ·· ·· ·· ·· ··						, ,

## **UNDERWRITING AND INVESTMENT EXHIBIT**

#### ANALYSIS OF CLAIMS UNPAID - PRIOR YEAR - NET OF REINSURANCE

		5	6		
Year to	Date 2	End of Curro	ent Quarter 4		
·		-			Estimated Claim
	0-		0-	Claima Ingurrad in	Reserve and Claim Liability
					December 31 of
Current Year	During the Year	of Prior Year	During the Year	(Columns 1 + 3)	Prior Year
	•		<del>-</del>		
				0	0
				0	0
				0	0
				0	0
				0	0
				0	0
58,065,535	93,803,094	10,555,363	68,103,551	68,620,898	78,886,325
				0	0
				0	
				0	0
				0	0
				u	
				0	0
				0	0
				u	
58,065,535	93,803,094	10,555,363	68,103,551	68,620,898	78,886,325
				0	0
				0	0
040 575		4 000 400	740.040	0 475 705	0.001.000
846,5/5		1,629,190		2,4/5,/65	2,601,233
58,912,110	93,803,094	12,184,553	68,823,397	71,096,663	81,487,558
	Year to 1 On Claims Incurred Prior to January 1 of Current Year	On Claims Incurred Prior to January 1 of Current Year On Claims Incurred During the Year On Standard S	Year to Date         End of Curr           1         2           On Claims Incurred Prior to January 1 of Current Year         On Claims Incurred During the Year           Dec. 31 of Prior Year           58,065,535         93,803,094           10,555,363           3846,575         11,629,190	Year to Date	Year to Date

<sup>(</sup>a) Excludes \$ ...... loans or advances to providers not yet expensed.

#### NOTE 1 Summary of Significant Accounting Policies and Going Concern

#### Accounting Practices

Accounting Practices
The accompanying financial statements of Martin's Point Generations Advantage, Inc. (the "Company") have been prepared in conformity with the National Association of Insurance Commissioners ("NAIC") Annual Statement Instructions and in accordance with accounting practices prescribed or permitted by the NAIC Accounting Practices and Procedures Manual, subject to any deviations prescribed or permitted by the Maine Bureau of Insurance (the "Bureau"). There were no deviations from NAIC prescribed or permitted by the Bureau in 2022 or 2023.

A table reconciling income and surplus between the practices prescribed and permitted by the State of Maine and NAIC SAP basis for the current reporting period and the prior year-end is shown below

	SSAP#	F/S Page	F/S Line #	2023	2022
NET INCOME (1) State basis (Page 4, Line 32, Columns 2 & 4)	XXX	XXX	xxx	\$ 6,395,332	\$ (17,529,061)
(2) State Prescribed Practices that are an increase/ (decrease) from NAIC SAP:					
(3) State Permitted Practices that are an increase/(decrease) from NAIC SAP:					
(4) NAIC SAP (1-2-3=4)	XXX	XXX	XXX	\$ 6,395,332	\$ (17,529,061)
SURPLUS (5) State basis (Page 3, Line 33, Columns 3 & 4)	XXX	XXX	xxx	\$ 98,586,415	\$ 86,149,288
(6) State Prescribed Practices that are an increase/(decrease	) from NAIC SA	AP:			
(7) State Permitted Practices that are an increase/(decrease)	from NAIC SAF	<b>&gt;</b> :			
(8) NAIC SAP (5-6-7=8)	XXX	XXX	XXX	\$ 98,586,415	\$ 86,149,288

#### Use of Estimates in the Preparation of the Financial Statements

The preparation of financial statements in conformity with Statutory Accounting Principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. It also requires disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates.

#### Accounting Policy

Expenses incurred in connection with acquiring new insurance business, including acquisition costs such as sales commissions, are charged to operations as incurred. Premiums paid by subscribers prior to the effective date are recorded on the balance sheet as advance premiums and subsequently credited to income as earned during the coverage period.

In addition, the Company uses the following accounting policies:

- 1.Short-term money market mutual funds are stated at market value and short-term bonds are stated at amortized cost.
- 2.Bonds are stated at amortized cost.
   3.Common stocks are stated at market value.
- 4.The Company does not have any preferred stock. 5.The Company does not have any mortgage loans
- 6. The Company's loan-backed securities are carried at amortized cost. The Company reports the adjustment methodology on an account basis as opposed to each individual security and accounts for all of the securities on a retrospective basis.

  7.The Company does not have any investments in subsidiaries, controlled or affiliated companies.

- 8. The Company does not have any investments in joint ventures, partnerships, or limited liability companies.

  9. The Company does not have any derivative instruments.

  10. The Company does not include anticipated investment income in calculating a premium deficiency.

  11. The Company's reported unpaid claims are based on actuarial estimates. The claims adjustment expenses are estimated at approximately 2% of unpaid claims. Liabilities for unpaid claims and claims adjustment expense are based on assumptions and estimates and while management believes such estimates are reasonable,
- the ultimate liability may be in excess of or less than the amount provided.

  12. The Company does not have any capital assets and therefore no capitalization policy.

  13. Pharmaceutical rebates receivables consist of reasonably estimated amounts and billed amounts. Both the billed amount and the estimated amount shall be admitted assets subject to the following conditions: Estimated amounts shall be related solely to actual prescriptions filled during the 3 months immediately preceding the reporting date. Other rebates receivables are non-admitted.
- Going Concern

Management has no significant doubts about the Company's ability to continue as a going concern

#### NOTE 2 Accounting Changes and Corrections of Errors

None.

#### NOTE 3 Business Combinations and Goodwill

None.

- Statutory Purchase Method None
- Statutory Merger

None

C. Assumption Reinsurance

D Impairment Loss

None.

Subcomponents and Calculation of Adjusted Surplus and Total Admitted Goodwill None

#### NOTE 4 Discontinued Operations

None

- Change in Plan of Sale of Discontinued Operation
- Nature of Any Significant Continuing Involvement with Discontinued Operations After Disposal C.
- D. Equity Interest Retained in the Discontinued Operation After Disposal None

#### NOTE 5 Investments

- Mortgage Loans, including Mezzanine Real Estate Loans
- Debt Restructuring None
- C Reverse Mortgages

1.For fixed-rate agency mortgage-backed securities, the Company calculates prepayment speeds utilizing Mortgage Industry Advisory Corporation (MIAC) Mortgage Industry Medians (MIMs). MIMs are derived from a semi-monthly dealer-consensus survey of long-term prepayment projections. For other mortgage-backed, loan-backed, and structured securities, the Company utilizes prepayment assumptions from Moody's Analytics. Moody's applies a flat economic credit model and utilizes a vector of multiple monthly speeds as opposed to a single speed for more robust projections. In instances where Moody's projections are not available, the Company uses data from Reuters, which utilizes the median prepayment speed from contributors' models.

2. All securities with a recognized other-than-temporary impairment, disclosed in the aggregate, classified on the basis for the other-than-temporary impairment: The Company has no securities to report per the table below.

- (2) OTTI recognized 1st Quarter
  - a. Intent to sell
  - b. Inability or lack of intent to retain the investment in the security for a period of time sufficient to recover the amortized cost basis
  - c. Total 1st Quarter (a+b)
  - OTTI recognized 2nd Quarter
  - d. Intent to sell
  - e. Inability or lack of intent to retain the investment in the security for a period of time sufficient to recover the amortized cost basis
  - f. Total 2nd Quarter (d+e)
  - OTTI recognized 3rd Quarter
  - g. Intent to sell
  - h. Inability or lack of intent to retain the investment in the security for a period of time sufficient to recover the amortized cost basis
  - i. Total 3rd Quarter (g+h)
  - OTTI recognized 4th Quarter
  - j. Intent to sell
  - k. Inability or lack of intent to retain the investment in the security for a period of time sufficient to recover the amortized cost basis
  - I. Total 4th Quarter (j+k)
  - m. Annual Aggregate Total (c+f+i+l)

1 Amortized Cost Basis Before Other-than- Temporary Impairment	2 Other-than- Temporary Impairment Recognized in Loss	3 Fair Value 1 - 2
		\$ -
		\$ -
\$ -	\$ -	\$ -
		\$ -
		-
\$ -	\$ -	\$ -
		\$ -
		\$ -
\$ -	\$ -	\$ -
		\$ -
		\$ -
\$ -	\$ -	\$ -
	\$ -	

(3)						
1	2	3	4	5	6	7
CUSIP	Book/Adjusted Carrying Value Amortized Cost Before Current Period OTTI	Present Value of Projected Cash Flows	Recognized Other-Than- Temporary Impairment	Amortized Cost After Other-Than- Temporary Impairment	Fair Value at time of OTTI	Date of Financial Statement Where Reported
Total	XXX	XXX	\$ -	XXX	XXX	XXX

a) The aggregate amount of unrealized losses:

1. Less than 12 Months 101,111 2. 12 Months or Longer 573,032

b)The aggregate related fair value of securities with unrealized losses:

1. Less than 12 Months \$ 4.950.833 2. 12 Months or Longer 3,614,416

- (5) The Company considers the following general categories of information in reaching the conclusion that impairments are other-than-temporary:
  - Performance of investments over a twelve-month period
  - Volatility in the market
  - Securities ratings ·Ability to hold to maturity
- Dollar Repurchase Agreements and/or Securities Lending Transactions
  - (1) None.

- Repurchase Agreements Transactions Accounted for as Secured Borrowing F.
  - (1) None.
- G. Reverse Repurchase Agreements Transactions Accounted for as Secured Borrowing
- Repurchase Agreements Transactions Accounted for as a Sale
  - (1) None.
- Reverse Repurchase Agreements Transactions Accounted for as a Sale Ι.
  - (1) None.
- Real Estate (1) None.
- Low Income Housing tax Credits (LIHTC)
  - (1) None.
- Restricted Assets

Restricted Assets (Including Pledged)							-				
		1		2		3	4		5	6 Gross	7
Restricted Asset Category	(A a R	otal Gross dmitted & Non- dmitted) estricted from Current Year	(A a R	otal Gross dmitted & Non- idmitted) destricted from Prior Year	(D	crease/ ecrease) minus 2)	Total Current Year Non- admitted Restricted	F	Total Current Year Admitted Restricted I minus 4)	(Admitted & Non- admitted) Restricted to Total Assets (a)	Admitted Restricted to Total Admitted Assets (b)
a. Subject to contractual obligation for which liability is not shown					\$	_		\$	-	0.000	0.000
b. Collateral held under security lending agreements					\$	_		\$	-	0.000	0.000
c. Subject to repurchase agreements					\$	-		\$	-	0.000	0.000
d. Subject to reverse repurchase agreements					\$	-		\$	-	0.000	0.000
e. Subject to dollar repurchase agreements f. Subject to dollar reverse repurchase agreements					\$	-		\$	-	0.000	0.000
g. Placed under option contracts					\$ \$	-		\$ \$	-	0.000 0.000	0.000 0.000
· ·					Φ	-		Φ	-	0.000	0.000
h. Letter stock or securities restricted as to sale - excluding FHLB capital stock					\$	-		\$	-	0.000	0.000
i. FHLB capital stock					\$	-		\$	-	0.000	0.000
j. On deposit with states	\$	621,565	\$	616,961	\$	4,604		\$	621,565	0.002	0.002
k. On deposit with other regulatory bodies					\$	-		\$	-	0.000	0.000
I. Pledged collateral to FHLB (including assets backing funding agreements)					\$	-		\$	-	0.000	0.000
m. Pledged as collateral not captured in other categories					\$	_		\$	-	0.000	0.000
n. Other restricted assets					\$	-		\$	-	0.000	0.000
o. Total Restricted Assets (Sum of a through n)	\$		\$	616,961	\$	4,604	\$ -	\$	621,565	0.002	0.002

- (a) Column 1 divided by Asset Page, Column 1, Line 28
- (b) Column 5 divided by Asset Page, Column 3, Line 28
- Detail of Assets Pledged as Collateral Not Captured in Other Categories (Contracts That Share Similar Characteristics, Such as Reinsurance and Derivatives, Are Reported in the Aggregate)
- 3. Detail of Other Restricted Assets (Contracts That Share Similar Characteristics, Such as Reinsurance and Derivatives, Are Reported in the Aggregate)
- 4. Collateral Received and Reflected as Assets Within the Reporting Entity's Financial Statements
- Working Capital Finance Investments None.
- Offsetting and Netting of Assets and Liabilities None. N.

Ο.

- 5GI Securities None.
- Short Sales
- Prepayment Penalty and Acceleration Fees

General Account

- 1. Number of CUSIPs
- 2. Aggregate Amount of Investment Income
- Reporting Entity's Share of Cash Pool by Asset Type

Asset Type Percent Share (1) Cash 96% (2) Cash Equivalents 4%

10.2

(3) Short-Term Investments

0% 100%

(4) Total

#### NOTE 6 Joint Ventures, Partnerships and Limited Liability Companies

The Company has no investments in joint ventures, partnerships, or limited liability companies.

The Company has no impaired investments in joint ventures, partnerships, or limited liability companies.

#### NOTE 7 Investment Income

Due and accrued investment income was excluded from surplus on the following bases: We have no investment income due and accrued excluded from surplus.

The Company did not accrue investment income that was non-admitted at December 31, 2022.

#### NOTE 8 Derivative Instruments

Derivatives under SSAP No. 86—Derivatives

NOTE 9 Income Taxes

The Company is not subject to Federal Income taxes.

#### NOTE 10 Information Concerning Parent, Subsidiaries, Affiliates and Other Related Parties

A.Nature of the relationship involved

The Company is a wholly owned subsidiary of Martin's Point Health Care, Inc. (MPHC).

B&C. Description of the transactions involved, and the dollar amounts of transactions

The Company has an arrangement with MPHC where it will pay MPHC's delivery system for covered services. The payments will consist of fee-for-service payments minus any applicable coinsurance, copayments, deductibles, and contractual adjustments. The Company paid MPHC \$704,466 and \$2,807,963 in 2023 and 2022, respectively

The Company has incentive, risk sharing, and other arrangements with MPHC with respect to members who receive primary care from providers employed by MPHC. Under these arrangements, the Company makes payments to MPHC as follows:

Cost of Care Risk Share Arrangement: The Company and MPHC accept joint responsibility for managing the cost of care for members who receive primary care through MPHC's delivery system. In recognition of this joint responsibility, the parties agree to participate in a cost of care risk share arrangement. The Company makes payments to MPHC when medical loss ratio results are less than targets. The Company receives payments from MPHC when medical loss ratio results are greater than targets. Under this arrangement, the Company received \$0 and \$250,000 from MPHC for 2023 and 2022, respectively.

Primary Care Payment Model: The Company and MPHC entered into a payment agreement whereby the Company agrees to make payments to MPHC based on performance of specified procedures. The Company paid MPHC \$0 and \$2,044,733 for 2023 and 2022, respectively.

Capitation: The Company and MPHC entered into a payment agreement whereby the Company agrees to make payments to MPHC based on capitation. The Company paid MPHC \$1,420,048 and \$5,698,818 for 2023 and 2022, respectively.

Prep Sheet Payments: The Company and MPHC entered into a payment agreement whereby the Company agrees to make payments to MPHC based on the completion of coding prep sheets prior to member annual visits. The Company paid MPHC \$207,949 and \$641,701 for 2023 and 2022, respectively.

Population Based Incentives: The Company and MPHC entered into a payment agreement whereby the Company agrees to make payments based on MPHC's performance against pre-determined quality metrics. The Company paid MPHC \$0 and \$816,979 for 2023 and 2022, respectively.

D. Amounts Due to or from Related Parties

At March 31, 2023, the Company reported a net of \$3,914,636 due to MPHC for amounts applicable to 2023.

E.Guarantees or Contingencies for Related Parties

Effective November 23, 2015, MPHC, the Guarantor, and the Company, the Primary Obligor, entered into an Unconditional Financial Guaranty with the Maine Bureau of Insurance to secure the Superintendent's conditional approval and licensing of the Primary Obligor to enter into the insurance business in the State of Maine. The Guarantor absolutely and unconditionally guarantees to the Superintendent and the Superintendent's successors and assigns, that if the Primary Obligor at any time fails to maintain capital and surplus at a level no less that the greater of the product of its authorized control level risk-based capital and 3.0 or the minimum requirements for capital and surplus, the Guarantor shall automatically pay such sums or deposits to the Primary Obligor as are necessary to establish and maintain capital and surplus at a level no less that the greater of the product of its authorized control level risk-based capital and 3.0 or the minimum requirements for capital and surplus.

F.Management, Service Contracts, Cost Sharing Arrangements

The Company purchases certain marketing, administrative, managerial, and other services required by the Company under a Management Services Agreement with MPHC. Management fees charged to the operations for the period ended March 31, 2023 and December 31, 2022 were \$8,639,810 and \$33,158,725, respectively

G.Nature of Relationships that Could Affect Operations: None.

H.Amount Deducted for Investment in Upstream Company: None.

I.Detail of Investments in Affiliates Greater than 10% of Admitted Assets: None.

J.Write-down for Impairments of Investments in Subsidiary, Controlled or Affiliated Companies: None.

K.Investment in Foreign Insurance: None.

L.Investment in Downstream Noninsurance Holding Company: None.

All SCA Investments

None.

- Investment in Insurance SCAs N.
  - (1) None.
- SCA or SSAP 48 Entity Loss Tracking

#### NOTE 11 Debt

- Debt including Capital Notes: None
- FHLB (Federal Home Loan Bank) Agreements None.

#### NOTE 12 Retirement Plans, Deferred Compensation, Postemployment Benefits and Compensated Absences and Other Postretirement Benefit Plans

Defined Benefit Plan

None.

- Investment Policies and Strategies: None.
- C. The fair value of each class of plan assets None.
- Basis used to determine the long-term rate-of-return: None. D
- E. Defined Contribution Plan

Multiemployer Plans F.

Consolidated/Holding Company Plans G.

Postemployment Benefits and Compensated Absences

None.

Impact of Medicare Modernization Act on Postretirement Benefits (INT 04-17)

None.

#### NOTE 13 Capital and Surplus, Dividend Restrictions and Quasi-Reorganizations

- The Company has no capital stock.
- В. The Company has no preferred stock
- C. The Company has no dividend restrictions.
- D The Company does not pay dividends.
- No portion of the entity's profits may be paid as ordinary dividends.
- The Company has no unassigned surplus funds
- G The Company has no advances to surplus
- Η. The Company has no shares of stock held for special purposes.
- I. The Company has no special surplus funds, changes in the balances of special purpose funds are not applicable.
- The portion of unassigned funds (surplus) represented or reduced by cumulative unrealized gains and losses is
- The Company has no surplus adjustments due to cumulative unrealized losses.

The Company issued the following surplus debentures or similar obligations: The Company has not issued any surplus notes or debentures or similar obligations.

- The impact of any restatement due to prior quasi-reorganizations is as follows: L.
  - The Company had no restatements due to prior quasi-reorganizations
- The Company has not been involved in any quasi-reorganizations during the past 10 years

#### NOTE 14 Liabilities, Contingencies and Assessments

Contingent Commitments

None

K.

В Assessments

The Company is subject to a guaranty fund administered by the State of Maine. Guaranty fund assessments are accrued at the time of insolvencies. The Company is not currently aware of any impending solvency issues.

Gain Contingencies

None.

D Claims related extra contractual obligations and bad faith losses stemming from lawsuits

None.

Joint and Several Liabilities

All Other Contingencies

None.

#### NOTE 15 Leases

- Lessee Operating Lease: None.
- Lessor Leases

None

#### NOTE 16 Information About Financial Instruments With Off-Balance Sheet Risk and Financial Instruments With Concentrations of Credit Risk

None.

#### NOTE 17 Sale, Transfer and Servicing of Financial Assets and Extinguishments of Liabilities

Α. Transfers of Receivables Reported as Sales

Transfer and Servicing of Financial Assets

None.

C. Wash Sales

#### NOTE 18 Gain or Loss to the Reporting Entity from Uninsured Plans and the Uninsured Portion of Partially Insured Plans

ASO Plans:

None.

В ASC Plans:

None.

Medicare or Similarly Structured Cost Based Reimbursement Contract
The Medicare Advantage prescription drug program is referred to as Part D. Settlement amounts relating to the Part D program are reported as amounts held in relation to uninsured plans as follows:

The Company reported \$5,954,256 as accounts receivable relating to uninsured plans as of March 31, 2023. The portion of this receivable related to the amounts received from manufacturers as part of Coverage Gap Discount Program is non-admitted for Statutory reporting. The Company reported \$4,912,837 as an admitted receivable and \$5,809,128 as admitted receivables at March 31, 2023 and December 31, 2022, respectively.

Low Income Cost Sharing (LICS) - \$945,365

Low-income members have some or the entire member cost share of their benefits paid for by CMS. A prospective payment rate is established during the bid process. Actual expenses are compared to the prospective amounts paid with reconciliation to or from CMS to settle the difference. The company estimate that the prospective payment did not fully cover the CMS LICS obligation.

Federal Reinsurance - \$1,057,054

Through the Federal reinsurance program, CMS pays 80% of the costs members incur through their Part D benefit beyond the true out-of-pocket (TrOOP) threshold. During the annual bid process, a prospective amount is defined to represent the projected amount Federal Reinsurance will cover. With the close of the year, the prospective payment is reconciled with actual experience. Applicable expenses beyond the prospective reimbursement are accrued as a receivable and amounts below the prospective payable held as a liability.

Coverage Gap Discount Program - \$3,951,837

The Company reported amounts due from pharmaceutical manufacturers in connection with the coverage gap discount program of \$1,436,625 and \$5,593,467 for plan year 2023 and 2022 as accounts receivable related to uninsured plans. These amounts are non-admitted. Additionally, the Company reported a receivable of \$2,515,212 related to the coverage gap discount program for plan year 2022.

#### NOTE 19 Direct Premium Written/Produced by Managing General Agents/Third Party Administrators

#### NOTE 20 Fair Value Measurements

(1) Fair Value Measurements at Report	ing Date						
Description for each class of asset or liability		(Level 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)		Total
a. Assets at fair value Common Stocks	\$	32,291,205				\$	32,291,205
Total assets at fair value/NAV	Ф	32 201 205	¢	¢	e	¢	32 201 205

Description for each class of asset or liability	(Level 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)	Total
b. Liabilities at fair value					
Total liabilities at fair value	\$ -	\$ -	\$ -	\$ -	\$ -

(2) Fair Value Measurements in (Level 3) of the Fair Value hierarchy

Description	Ending Balance as of Prior Quarter End	Transfers into Level 3	Transfers out of Level 3	Total gains and (losses) included in Net Income	Total gains and (losses) included in Surplus	Purchases	Issuances	Sales	Settlements	Ending Balance for Current Quarter End
a. Assets										
Total Assets	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -

Description	Ending Balance as of Prior Quarter End	Transfers into Level 3	Transfers out of Level 3	Total gains and (losses) included in Net Income	Total gains and (losses) included in Surplus	Purchases	Issuances	Sales	Settlements	Ending Balance for Current Quarter End
b. Liabilities										
Total Liabilities	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -

- (3) Company input
- (4) Company input
- (5) Company input
- Company input

Aggregate fair value for all financial instruments and the level within the fair value hierarchy in which the fair value measurements in their entirety fall.

Type of Financial Instrument	Aggregate Fair Value	Admitted Assets	(	(Level 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)	Not Practicable (Carrying Value)
Bonds	\$ 20,977,752	\$ 22,197,784	\$	22,092,153	\$ 105,631	·		
Common Stocks	\$ 32,291,205	\$ 32,291,205	\$	32,291,205				

#### NOTE 21 Other Items

Unusual or Infrequent Items None

В. Troubled Debt Restructuring: Debtors None.

Other Disclosures

None.

D. **Business Interruption Insurance Recoveries** 

None.

State Transferable and Non-transferable Tax Credits

F Subprime Mortgage Related Risk Exposure

None.

G. **Retained Assets** 

Insurance-Linked Securities (ILS) Contracts

None

The Amount That Could Be Realized on Life Insurance Where the Reporting Entity is Owner and Beneficiary or Has Otherwise Obtained Rights to Control the Policy

None.

#### NOTE 22 Events Subsequent

Type I - Recognized Subsequent Events:

Subsequent events have been considered through April 24, 2023 for the statutory statements issued on April 24, 2023.

Type II - Nonrecognized Subsequent Events:

#### NOTE 23 Reinsurance

Ceded Reinsurance Report

Section 1 - General Interrogatories

1.Are any of the reinsurers, listed in Schedule S as non-affiliated, owned in excess of 10% or controlled, either directly or indirectly, by the Company or by any representative, officer, trustee, or director of the Company?

Yes () No (X)

2.Have any policies issued by the Company been reinsured with a company chartered in a country other than the United States (excluding U.S. Branches of such companies) that is owned in excess of 10% or controlled directly or indirectly by an insured, a beneficiary, a creditor or an insured or any other person not primarily engaged in the insurance business?

Yes ( ) No (X)

Section 2 - Ceded Reinsurance Report - Part A

1.Does the company have any reinsurance agreements in effect under which the reinsurer may unilaterally cancel any reinsurance for reasons other than for nonpayment of premium or other similar credit?

Yes ( ) No (X)

2.Does the reporting entity have any reinsurance agreements in effect such that the amount of losses paid or accrued through the statement date may result in a payment to the reinsurer of amounts that, in aggregate and allowing for offset of mutual credits from other reinsurance agreements with the same reinsurer, exceed the total direct premium collected under the reinsured policies?

Yes () No (X)

Section 3 - Ceded Reinsurance Report - Part B

1.What is the estimated amount of the aggregate reduction in surplus, (for agreements other than those under which the reinsurer may unilaterally cancel for reasons other than for nonpayment of premium or other similar credits that are reflected in Section 2 above) of termination of ALL reinsurance agreements, by either party, as of the date of this statement?

2. Have any new agreements been executed, or existing agreements amended, since January 1 of the year of this statement, to include policies or contracts that were in force or which had existing reserves established by the Company as of the effective date of the agreement?

Uncollectible Reinsurance

None

- C. Commutation of Reinsurance Reflected in Income and Expenses.
   None.

D. Certified Reinsurer Rating Downgraded or Status Subject to Revocation

<u>----</u>

E. Reinsurance Credit None.

#### NOTE 24 Retrospectively Rated Contracts & Contracts Subject to Redetermination

- A. Method used to estimate accrued retrospective premium advances. None
- B. Disclosure of accrued retrospective premiums. None.
- C. Disclosure of the amount of net premiums written. None.

D. Medical loss ratio rebates required pursuant to the Public Health Service Act

dical loss ratio repates required pursuant to the Public He	aith :	Service Act.									
		1		2			3		4		5
									Other		
			٤	Small Group	)	,	ge Group	Ca	tegories with	1	
	_	Individual		Employer		Eı	mployer		Rebates		Total
Prior Reporting Year											
(1) Medical loss ratio rebates incurred	\$	1,094,929	\$		-	\$	-	\$		\$	1,094,929
(2) Medical loss ratio rebates paid	\$	11,838,205	\$		-	\$	-	\$		\$	11,838,205
(3) Medical loss ratio rebates unpaid	\$	1,094,929	\$		-	\$	-	\$		\$	1,094,929
(4) Plus reinsurance assumed amounts		XXX		XXX			XXX		XXX		
(5) Less reinsurance ceded amounts		XXX		XXX			XXX		XXX		
(6) Rebates unpaid net of reinsurance		XXX		XXX			XXX		XXX	\$	1,094,929
Current Reporting Year-to-Date											
(7) Medical loss ratio rebates incurred	\$	-	\$		-	\$	-	\$		\$	-
(8) Medical loss ratio rebates paid										\$	-
(9) Medical loss ratio rebates unpaid	\$	1,094,929								\$	1,094,929
(10) Plus reinsurance assumed amounts		XXX		XXX			XXX		XXX		
(11) Less reinsurance ceded amounts		XXX		XXX			XXX		XXX		
(12) Rebates unpaid net of reinsurance		XXX		XXX			XXX		XXX	\$	1,094,929

- E. Risk Sharing Provisions of the Affordable Care Act
  - (1) Did the reporting entity write accident and health insurance premium which is subject to the Affordable Care Act risk sharing provisions (YES/NO)?

Yes [ ] No [X]

#### NOTE 25 Change in Incurred Claims and Claim Adjustment Expenses

A.Reserves as of December 31, 2022 were \$79,838,420. As of March 31, 2023, \$58,890,235 has been paid for incurred claims and claim adjustment expenses attributable to insured events of the prior year. Reserves remaining for prior years are \$10,265,427 as a result of re-estimation of unpaid claims and claim adjustment expenses. After consideration of \$6,488,008 of redundancy at December 31, 2022, there has been \$4,736,997 favorable prior-year development since December 31, 2022. The favorable development is generally the result of ongoing analysis of recent development trends. Estimates are increased or decreased as additional information becomes known regarding individual claims.

B.Significant changes in methodologies and assumptions used in calculating the liability: None

#### NOTE 26 Intercompany Pooling Arrangements

None

#### NOTE 27 Structured Settlements

None.

#### NOTE 28 Health Care Receivables

A. Pharmaceutical Rebate Receivables

Pharmaceutical rebates receivables consist of reasonably estimated amounts and billed amounts. Both the billed amount and the estimated amount shall be admitted assets subject to the following conditions: Estimated amounts shall be related solely to actual prescriptions filled during the 3 months immediately preceding the reporting date. Other rebates receivables are non-admitted.

B. Risk-Sharing Receivables

The Company participates in risk sharing arrangements with area health care provider systems. In determining appropriate receivables or liabilities for these arrangements, the valuation process reflects actual experience during the performance period for each contract. Where actual experience is not yet complete, experienced actuarial modeling and judgement, consistent with the Company's methods employed for IBNP and Accrued Retrospective Premiums, are applied to reflect the most likely performance of each risk sharing contract. Reserves are applied to estimated risk sharing receivables as provisions for actual experience.

Estimated balance of risk sharing receivables as reported on the prior year financial statements for evaluation periods ending in the current year: None

Estimated balance of risk sharing receivables as reported on the current year financial statements for evaluation periods ending in the current year and the following year: None

Risk sharing receivables billed as determined after the annual evaluation period: None.

Risk sharing receivables not yet billed: None.

Amounts received from providers as payments under risk sharing contracts: None.

#### NOTE 29 Participating Policies

None

#### NOTE 30 Premium Deficiency Reserves

- 1. Liability carried for premium deficiency reserves
- 2. Date of the most recent evaluation of this liability
- 3. Was anticipated investment income utilized in the calculation?

\$ 04/20/2023

Yes [ ] No [X]

#### NOTE 31 Anticipated Salvage and Subrogation

The Company does not take into account an estimate of anticipated salvage or subrogation in its determination of its liability for unpaid claims.

## **GENERAL INTERROGATORIES**

## PART 1 - COMMON INTERROGATORIES

#### **GENERAL**

1.1	Did the reporting entity experience any material transactions requiring Domicile, as required by the Model Act?	g the filing of Dis	closure of Material Trans	sactions with the Sta	ite of		Yes [	]	No [	[ X ]
1.2	If yes, has the report been filed with the domiciliary state?						Yes [	]	No [	[ ]
2.1	Has any change been made during the year of this statement in the oreporting entity?						Yes [	]	No	[ X ]
2.2	If yes, date of change:					·····_				
3.1	Is the reporting entity a member of an Insurance Holding Company S is an insurer?						Yes [	Х ]	No [	1
3.2	Have there been any substantial changes in the organizational chart	since the prior q	uarter end?				Yes [	]	No [	[ X ]
3.3	If the response to 3.2 is yes, provide a brief description of those chan	-								
3.4	Is the reporting entity publicly traded or a member of a publicly traded	d group?					Yes [	]	No	[ X ]
3.5	If the response to 3.4 is yes, provide the CIK (Central Index Key) cod									
4.1	Has the reporting entity been a party to a merger or consolidation dur		Yes [	]	No [	[ X ]				
4.2	If yes, provide the name of the entity, NAIC Company Code, and stat ceased to exist as a result of the merger or consolidation.									
	1 Name of Entity		2 NAIC Company Code	3 State of Domicile	;					
5.	If the reporting entity is subject to a management agreement, includir in-fact, or similar agreement, have there been any significant change If yes, attach an explanation.	es regarding the t	erms of the agreement of	or principals involved	d?		] No	) [ X	] N.	/A [ ]
6.1	State as of what date the latest financial examination of the reporting	g entity was made	e or is being made				1	12/31	/2018	
6.2	State the as of date that the latest financial examination report becardate should be the date of the examined balance sheet and not the control of the examined balance sheet and not the examined balance sheet and not the control of the examined balance sheet and not the examined balance sheet and not the control of the examined balance sheet and not the control of the examined balance sheet and not the control of the examined balance sheet and not the control of the examined balance sheet and not the examined balance sheet and not the control of the examined balance sheet and not the control of the examined balance sheet and not the						1	12/31	/2018	
6.3	State as of what date the latest financial examination report became the reporting entity. This is the release date or completion date of the date).	e examination rep	port and not the date of t	the examination (bal	ance she	eet	C	06/13	/2020	ı
6.4	By what department or departments?  Bureau of Insurance of the State of Maine									
6.5	Have all financial statement adjustments within the latest financial ex statement filed with Departments?	•				Yes [	] No	) [	] N	/A [ X ]
6.6	Have all of the recommendations within the latest financial examinati	ion report been o	complied with?			Yes [ X	] No	] (	] N.	/A [
7.1	Has this reporting entity had any Certificates of Authority, licenses or revoked by any governmental entity during the reporting period?						Yes [	. ]	No [	[ X ]
7.2	If yes, give full information:									
8.1	Is the company a subsidiary of a bank holding company regulated by	y the Federal Res	serve Board?				Yes [	]	No [	[ X ]
8.2	If response to 8.1 is yes, please identify the name of the bank holding	0 , ,								
8.3	Is the company affiliated with one or more banks, thrifts or securities	firms?					Yes [	]	No [	[ X ]
8.4	If response to 8.3 is yes, please provide below the names and locatic regulatory services agency [i.e. the Federal Reserve Board (FRB), th Insurance Corporation (FDIC) and the Securities Exchange Commission	ne Office of the C	omptroller of the Curren	cy (OCC), the Feder	al Depos					
	1 Affiliate Name	l l	2 Location (City, State)	3 FRB	4 OCC	5 FDIC	6 SEC			

# **GENERAL INTERROGATORIES**

9.1	similar functions) of the reporting entity subject to a code of ethics, which includes the following standards?  (a) Honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships;							
	<ul><li>(b) Full, fair, accurate, timely and understandable disclosure in the periodic reports required to be filed by the report</li><li>(c) Compliance with applicable governmental laws, rules and regulations;</li><li>(d) The prompt internal reporting of violations to an appropriate person or persons identified in the code; and</li><li>(e) Accountability for adherence to the code.</li></ul>	ting entity;						
9.11								
9.2 9.21	Has the code of ethics for senior managers been amended?			Yes [	] No [	Х ]		
9.3 9.31	Have any provisions of the code of ethics been waived for any of the specified officers?			Yes [	] No [	Х ]		
	FINANCIAL							
10.1 10.2	Does the reporting entity report any amounts due from parent, subsidiaries or affiliates on Page 2 of this statement If yes, indicate any amounts receivable from parent included in the Page 2 amount:							
	INVESTMENT							
	Were any of the stocks, bonds, or other assets of the reporting entity loaned, placed under option agreement, or of use by another person? (Exclude securities under securities lending agreements.)			Yes [	] No [	Х ]		
12.	Amount of real estate and mortgages held in other invested assets in Schedule BA:							
13. 14.1 14.2	Amount of real estate and mortgages held in short-term investments:  Does the reporting entity have any investments in parent, subsidiaries and affiliates?  If yes, please complete the following:							
		1 Prior Year-End Book/Adjusted Carrying Value		В	2 irrent Qua ook/Adjus arrying Va	sted		
	Bonds							
	Preferred Stock							
	Short-Term Investments							
	Mortgage Loans on Real Estate							
	All Other			\$				
14.27 14.28	Total Investment in Parent, Subsidiaries and Affiliates (Subtotal Lines 14.21 to 14.26)	.\$ .\$	0					
15.1 15.2	Has the reporting entity entered into any hedging transactions reported on Schedule DB?  If yes, has a comprehensive description of the hedging program been made available to the domiciliary state?  If no, attach a description with this statement.		Yes [		] No [ ] N/			
16.	For the reporting entity's security lending program, state the amount of the following as of the current statement da					^		
	16.1 Total fair value of reinvested collateral assets reported on Schedule DL, Parts 1 and 2							
	<ul> <li>16.2 Total book/adjusted carrying value of reinvested collateral assets reported on Schedule DL, I</li> <li>16.3 Total payable for securities lending reported on the liability page.</li> </ul>							
	10.0 Total payable for securities lending reported on the liability page			,		U		

# **GENERAL INTERROGATORIES**

Outsourcing of Criti	t with a qualified ban cal Functions, Custoo	ere all stocks, bonds and other s k or trust company in accordanc dial or Safekeeping Agreements equirements of the NAIC Financ	ce with Section 1, III - Co of the NAIC Financial (	Seneral Examination C Condition Examiners F	onsiderations, F. landbook?	Yes [	X ] No [
	1	W ( )		2			
US Bank NA	Name of Custo	odian(s)	50 S 16th St. 20th	Custodian Addr Floor, Philadelphia,			
For all agreements		th the requirements of the NAIC	Financial Condition Ex	xaminers Handbook, p	rovide the name,		
	1	2 Location(s)		3 Complete Expla	nation(s)		
	ne(s)						
	y changes, including mation relating theret	name changes, in the custodian o:	i(s) identified in 17.1 du	iring the current quarte	er?	Yes [	] No [ X
	l stodian	2 New Custodian	3 Date of Char	nge	4 Reason		
make investment de	ecisions on behalf of	vestment advisors, investment m the reporting entity. For assets the ment accounts"; "handle secur	hat are managed intern				
Asset Allocation	Name of Firm	or Individual LC	Affiliation				
		LU					
17.5097 For those to designated	irms/individuals listed with a "U") manage	d in the table for Question 17.5, of more than 10% of the reporting e	do any firms/individuals entity's invested assets	unaffiliated with the re?	eporting entity (i.e.	Yes [	X ] No [
		with the reporting entity (i.e. des				Yes [	] No [
For those firms or in table below.	ndividuals listed in the	e table for 17.5 with an affiliation	code of "A" (affiliated)	or "U" (unaffiliated), pr	rovide the information for the	he	
1		2		3	4	In	5 vestment
Central Registration		Name of Firm on ladicide of					inagement greement
Depository Number 109875				Entity Identifier (LEI)	Degistered With		MAN E:164
	Asset Allocation	Name of Firm or Individual and Management Co. LLC		Entity Identifier (LEI)	SEC	(II	MA) Filed
	Asset Allocation				SEC	(II DS.	
Have all the filing re If no, list exceptions  By self-designating a. Documentati security is no b. Issuer or obl c. The insurer It Has the reporting er	Asset Allocation quirements of the Pu  5GI securities, the re on necessary to pernot available. gor is current on all c as an actual expecta-	and Management Co. LLC	of the NAIC Investment owing elements for each curity does not exist or payments.	t Analysis Office been the self-designated 5GI an NAIC CRP credit rationals.	followed?security:	Yes [	X ] No [
Have all the filing re If no, list exceptions  By self-designating a. Documentati security is no b. Issuer or obl c. The insurer h  Has the reporting e  By self-designating a. The security o b. The reporting c. The NAIC De on a current d. The reporting	Asset Allocation	and Management Co. LLC	of the NAIC Investment owing elements for each curity does not exist or payments. Ontracted interest and pollowing elements of each collowing elements of eleme	t Analysis Office been ch self-designated 5Gl an NAIC CRP credit ra principal. ch self-designated PL for the security. legal capacity as a NF insurance regulators.	security: ating for an FE or PL  GI security:  RSRO which is shown	Yes [	X ] No [
Have all the filing re If no, list exceptions  By self-designating a. Documentati security is no b. Issuer or obl c. The insurer I Has the reporting e  By self-designating a. The security b. The reporting c. The NAIC De on a current I d. The reporting e  By assigning FE to FE fund: a. The shares w b. The reporting c. The security I January 1, 20	Asset Allocation	and Management Co. LLC	of the NAIC Investment owing elements for each curity does not exist or payments. Ontracted interest and public policy and NAIC CRP in its or examination by state at PL security with the State of the payments.	t Analysis Office been th self-designated 5GI an NAIC CRP credit ra principal.  The self-designated PL for the security. legal capacity as a Ni insurance regulators.  VO.  The following elements for the security.	followed?security: ating for an FE or PL  GI security: RSRO which is shown  of each self-designated	Yes [	X ] No [
Have all the filing re If no, list exceptions  By self-designating a. Documentati security is no b. Issuer or obl c. The insurer I Has the reporting e  By self-designating a. The security is b. The reporting c. The NAIC De on a current in d. The reporting e  By assigning FE to FE fund: a. The shares w b. The reporting c. The security I January 1, 20 d. The fund only e. The current in in its legal ca f. The public cree	Asset Allocation	and Management Co. LLC	of the NAIC Investment owing elements for each curity does not exist or payments. In the contracted interest and public policy of the contracted interest an	t Analysis Office been ch self-designated 5GI an NAIC CRP credit ra principal.  Inch self-designated PL for the security. legal capacity as a Ni insurance regulators.  Inch following elements for the security. RP in its legal capacity  Innual surveillance ass sed.	followed?  security: ating for an FE or PL  GI security:  RSRO which is shown  of each self-designated  v as an NRSRO prior to  igned by an NAIC CRP	Yes [	X ] No [

## **GENERAL INTERROGATORIES**

#### PART 2 - HEALTH

#### 1. Operating Percentages: 2.1 Do you act as a custodian for health savings accounts? ..... Yes [ ] No [ X ] 2.2 If yes, please provide the amount of custodial funds held as of the reporting date .......\$...... Yes [ ] No [ X ] Do you act as an administrator for health savings accounts? 2.3 If yes, please provide the balance of the funds administered as of the reporting date ......\$..... 2.4 Is the reporting entity licensed or chartered, registered, qualified, eligible or writing business in at least two states? ..... Yes [ X ] No [ ] 3. If no, does the reporting entity assume reinsurance business that covers risks residing in at least one state other than the state of 3.1

domicile of the reporting entity? ...

Yes [ ] No [ ]

# SCHEDULE S - CEDED REINSURANCE Showing All New Reinsurance Treaties - Current Year to Date

Showing All New Reinsurance Treaties - Current Year to Date           1         2         3         4         5         6         7         8         9         10										
1	2	3	4				8	9 Certified	10 Effective Date of	
NAIC Company Code	ID Number	Effective Date	Name of Reinsurer	Domiciliary Jurisdiction	Type of Reinsurance Ceded	Type of Business Ceded	Type of Reinsurer	Certified Reinsurer Rating (1 through 6)	Date of Certified Reinsurer Rating	
····		-								
·····										
····										
·····										
······										
······										
····										
·····										
		-							·····	
ļ									ļ	
·····									····	
·····										

## **SCHEDULE T - PREMIUMS AND OTHER CONSIDERATIONS**

Current Year to Date - Allocated by States and Territories 10 Federal Life and Annuity Premiums & Other Employees Health Active Status Accident and Health Property/ Casualty Total Columns 2 Renefite CHIP Title Program Premiums States, etc (a) Title XVIII Title XIX XXI Premiums sideratio Premiums Through 8 Contracts Alabama ..... ..0 ΑL Alaska 3. Arizona ΑZ .0 4. Arkansas AR ٥ 5. California ..... CA .N. .0 6. Colorado ... CO .N. .0 Connecticut ..... СТ .0 .N. DE .0 District of Columbia DC 9. 10. Florida . N 0 11. Georgia GΑ N 0 12. Hawaii ..... н N 0 13. Idaho .. ID .N. .0 Illinois .. 14. .0 IL .N. 15. IN .0 16. .0 17. Kansas KS .0 18 Kentucky. ΚY N ٥ 19. Louisiana ... LA N. .0 158.266.683 158.266.683 20. Maine ... .... ME Maryland ... 21. MD .N. ..0 22. Massachusetts ...... MA .0 23. Michigan .0 24. Minnesota MN .0 25. Mississippi ...... MS N 0 26. Missouri ..... MO N 0 27. Montana ..... MT .N. .0 28. Nebraska ..... NE .0 .N. 29. ... NV .0 30. New Hampshire ..... NH 21,504,091 21,504,091 31. New Jersey ..... NJ .0 32 New Mexico ...... NM ٥ 33. New York ..... NY .0 34. North Carolina ...... NC .N. .0 35. North Dakota ...... ND .0 .N. 36. Ohio ..... ОН .0 37. Oklahoma ..... 38. Oregon ..... OR .0 39 Pennsylvania ...... PΑ ٥ 40. Rhode Island ..... RI .N. .0 41. South Carolina ...... SC .N. .0 South Dakota ...... 42. SD .0 .N. 43. TN .0 44. 45. Utah .. UT 0 46. Vermont ..... VTN 0 47. Virginia ..... VA N 0 Washington ..... WA 48. .N. .0 West Virginia ..... WV 49. .N. .0 50. Wisconsin ..... WI .0 Wyoming ... 51. .0 52. American Samoa .... AS .0 53 Guam GU N ٥ Puerto Rico ...... 54. PR N. .0 U.S. Virgin Islands .. VI 55. ..N. .0 Northern Mariana 56. Islands ..... ..... MP .0 57. Canada .. ..... CAN .0 ..N... 58. Aggregate Other .... ОТ XXX .0 .0 .0 .0 .0 59. Subtotal .. .XXX. . 179, 770, 774 .0 .0 .0 .0 .179,770,774 0 Reporting Entity
Contributions for Employe 60. Benefit Plans XXX 179,770,774 179,770,774 61 Totals (Direct Business) XXX 0 0 0 0 DETAILS OF WRITE-INS 58001 XXX. 58002 XXX 58003. .XXX. Summary of remaining write-ins for Line 58 from 58998. overflow page ...... Totals (Lines 58001 through XXX. 0 . 0 . 0 .0 .0 0 0 58999. 58003 plus 58998)(Line 58 above) (a)

a) Active Status Counts:	
1. L - Licensed or Chartered - Licensed insurance carrier or domiciled RRG2	4. Q - Qualified - Qualified or accredited reinsurer0
2. R - Registered - Non-domiciled RRGs	5. N - None of the above - Not allowed to write business in the state 55
3. E - Eligible - Reporting entities eligible or approved to write surplus lines in the state 0	

# SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURER MEMBERS OF A HOLDING COMPANY GROUP PART 1 - ORGANIZATIONAL CHART

Martin's Point Health Care, Inc. FEIN #01-0353275 State of Maine Incorporated 04/13/1971

> Martin's Point Generations Advantage, Inc.
> Wholly Owned Subsidiary
> FEIN # 47-4682941
> NAIC Code #15850
> State of Maine Incorporated
> 7/31/2015

## **SCHEDULE Y**

# PART 1A - DETAIL OF INSURANCE HOLDING COMPANY SYSTEM

	2			-		1 -	8	T 0	40		10	40	T 44	4.5	40
1	2	3	4	5	6	/	8	9	10	11	_12	13	14	15	16
											Type	l†			
											of Control	Control			
											(Ownership,	is		Is an	
						Name of Securities			Relation-		Board,	Owner-		SCA	
						Exchange		Domi-	ship		Management,	ship		Filing	
		NAIC				if Publicly Traded	Names of	ciliary	to		Attorney-in-Fact,	Provide		Re-	
Group		Company	ID	Federal		(U.Ś. or	Parent, Subsidiaries	Loca-		Directly Controlled by	Influence,	Percen-	Ultimate Controlling	quired?	
Code	Group Name	Code	Number	RSSD	CIK	International)	Or Affiliates	tion	Entity	(Name of Entity/Person)	Other)	tage	Entity(ies)/Person(s)	(Yes/No)	*
	'		01-0353275				Martin's Point Health Care, Inc	ME	UDP	Martin's Point Health Care, Inc	Board of Directors	100.000	Martin's Point Health Care, Inc	NO	
		15850	47-4682941				Martin's Point Generations Advantage, Inc	ME		Martin's Point Health Care, Inc.	Board of Directors	100.000	Martin's Point Health Care, Inc	NO	
								l	J						
								1							
		I	1	1	1	i e	T. Control of the Con	1	1	1	i e	1			1

Asterisk Explanation	

## SUPPLEMENTAL EXHIBITS AND SCHEDULES INTERROGATORIES

The following supplemental reports are required to be filed as part of your statement filing. However, in the event that your company does not transact the type of business for which the special report must be filed, your response of NO to the specific interrogatory will be accepted in lieu of filing a "NONE" report and a bar code will be printed below. If the supplement is required of your company but is not being filed for whatever reason enter SEE EXPLANATION and provide an explanation following the interrogatory questions.

		Response
1.	Will the Medicare Part D Coverage Supplement be filed with the state of domicile and the NAIC with this statement?	NO
2.	AUGUST FILING  Will the regulator-only (non-public) Communication of Internal Control Related Matters Noted in Audit be filed with the state of domicile and electronically with the NAIC (as a regulator-only non-public document) by August 1? The response for 1st and 3rd quarters should be N/A. A NO response resulting with a bar code is only appropriate in the 2nd quarter.	N/A
1.	Explanation:	
٠.		
1.	Bar Code:  Medicare Part D Coverage Supplement [Document Identifier 365]	

## **OVERFLOW PAGE FOR WRITE-INS**

Additional Write-ins for Statement of Revenue and Expenses Line 6

Addition	ial Write-ins for Statement of Revenue and Expenses Line 6				
		Currer	nt Year	Prior Year	Prior Year Ended
		To I	Date	To Date	December 31
		1	2	3	4
		Uncovered	Total	Total	Total
0604.	Risk Sharing Revenue	XXX		0	
0697.	Summary of remaining write-ins for Line 6 from overflow page	XXX	0	0	0

## **SCHEDULE A - VERIFICATION**

Real Estate

		1	2
			Prior Year Ended
		Year to Date	December 31
1.	Book/adjusted carrying value, December 31 of prior year		
2.	Cost of acquired:		
	2.1 Actual cost at time of acquisition		
	2.2 Additional investment made after acquisition		
3.	Current year change in encumbrances		
4.	Total gain (loss) on disposals		
5.	Deduct amounts received on disposals		
6.	Total foreign exchange change in book/adjusted rying		
7.	Deduct current year's other than temporary impailment recognized		
8.	Deduct current year's depreciation		
9.	Book/adjusted carrying value at the end of current period (Lines 1+2+3+4-5+6-7-8)		
10.	Deduct total nonadmitted amounts		
11.	Statement value at end of current period (Line 9 minus Line 10)		

## **SCHEDULE B - VERIFICATION**

Mortgage Loans

	Mortgage Loans		
		1	2
			Prior Year Ended
		Year to Date	December 31
1.	Book value/recorded investment excluding accrued interest, December 31 of prior year		
2.	Cost of acquired:		
	2.1 Actual cost at time of acquisition		
	2.2 Additional investment made after acquisition		
3.	Capitalized deferred interest and other		
4.	Accrual of discount		
5.	Unrealized valuation increase (decrease)		
6.	Total gain (loss) on disposals		
7.	Deduct amounts received on disposals		
8.	Deduct amortization of premium and mortgage in the est plant and military dees		
9.	Total foreign exchange change in book value/receased invessment excess decrues attended in the control of the c		
10.	Deduct current year's other than temporary impairment recognized		
11.	Book value/recorded investment excluding accrued interest at end of current period (Lines 1+2+3+4+5+6-7-8+9-10)		
12.	Total valuation allowance		
13.	Subtotal (Line 11 plus Line 12)		
14.	Deduct total nonadmitted amounts		
15.	Statement value at end of current period (Line 13 minus Line 14)		

## **SCHEDULE BA - VERIFICATION**

Other Long-Term Invested Assets

	-	1	2
			Prior Year Ended
		Year to Date	December 31
1.	Book/adjusted carrying value, December 31 of prior year		
2.	Cost of acquired:		
	2.1 Actual cost at time of acquisition		
	2.2 Additional investment made after acquisition		
3.	Capitalized deferred interest and other		
4.	Accrual of discount		
5.	Unrealized valuation increase (decrease)		
6.	Total gain (loss) on disposals		
7.	Deduct amounts received on disposals		
8.	Deduct amortization of premium and depreciation		
9.	Total foreign exchange change in book/adjusted carrying value		
10.	Deduct current year's other than temporary impairment recognized		
11.	Book/adjusted carrying value at end of current period (Lines 1+2+3+4+5+6-7-8+9-10)		
12.	Deduct total nonadmitted amounts		
13.	Statement value at end of current period (Line 11 minus Line 12)		

## **SCHEDULE D - VERIFICATION**

Bonds and Stocks

		1	2
			Prior Year Ended
		Year to Date	December 31
1.	Book/adjusted carrying value of bonds and stocks, December 31 of prior year	70,872,069	68,862,159
2.	Cost of bonds and stocks acquired	5,567	36,870,482
3.	Accrual of discount	68,655	61,823
4.	Unrealized valuation increase (decrease)	2, 158, 086	(4,971,830)
5.	Total gain (loss) on disposals	273, 120	(453, 124)
6.	Deduct consideration for bonds and stocks disposed of		
7.	Deduct amortization of premium	7,333	53,345
8.	Total foreign exchange change in book/adjusted carrying value	0	
9.	Deduct current year's other than temporary impairment recognized		
10.	Total investment income recognized as a result of prepayment penalties and/or acceleration fees	0	
11.	Book/adjusted carrying value at end of current period (Lines 1+2+3+4+5-6-7+8-9+10)	54,488,989	70,872,069
12.	Deduct total nonadmitted amounts	0	
13.	Statement value at end of current period (Line 11 minus Line 12)	54,488,989	70,872,069

## **SCHEDULE D - PART 1B**

Showing the Acquisitions, Dispositions and Non-Trading Activity
During the Current Quarter for all Bonds and Preferred Stock by NAIC Designation

Daning a	ne Current Quarter to	2	2	/ Designation	5	6	7	8
	Book/Adjusted		3	4	5 Book/Adjusted	ნ Book/Adjusted	/ Book/Adjusted	8 Book/Adjusted
	Carrying Value	Acquisitions	Dispositions	Non-Trading Activity	Carrying Value	Carrying Value	Carrying Value	Carrying Value
	Beginning	During	During	During	End of	End of	End of	December 31
NAIC Designation	of Current Quarter	Current Quarter	Current Quarter	Current Quarter	First Quarter	Second Quarter	Third Quarter	Prior Year
BONDS								
1. NAIC 1 (a)	47,916,982	5,567	29,598,344	(267,899)	18,056,305	0	0	47,916,982
2. NAIC 2 (a)	3,619,271	0	0	416,577	4,035,848	0	0	3,619,271
3. NAIC 3 (a)	104,075	0	0	1,556	105,631	0	0	104,075
4. NAIC 4 (a)	0	0	0	0	0	0	0	
5. NAIC 5 (a)	0	0	0	0	0	0	0	
6. NAIC 6 (a)	. 0	0	0	0	0	0	0	
7. Total Bonds	51,640,328	5,567	29,598,344	150,234	22,197,784	0	0	51,640,328
PREFERRED STOCK								
8. NAIC 1			•			0		0
9. NAIC 2	0	0	0	0	0	0	0	0
9. NAIC 2	0	0	0	0	0	0	0	0
9. NAIC 2		0	0	0	0	0	0	0
9. NAIC 2	0	0	0	0	0	0	0	0
9. NAIC 2	0	0	0	0 0 0	0	0	0	0
9. NAIC 2 10. NAIC 3 11. NAIC 4 12. NAIC 5		000	0 0 0		0	0 0 0	0	0

(a) Book/Adjusted Carrying Value column for the end of the current reporting period includes the following amount of short-term and cash equivalent bonds by NAIC designation:

## **SCHEDULE DA - PART 1**

Short-Term Investments

	1  Book/Adjusted Carrying Value	2 Par Value	3 Actual Cost	4 Interest Collected Year-to-Date	5 Paid for Accrued Interest Year-to-Date
770999999 Totals	0	XXX	0	0	0

## **SCHEDULE DA - VERIFICATION**

Short-Term Investments

		1	2
		Year To Date	Prior Year Ended December 31
1.	Book/adjusted carrying value, December 31 of prior year	3,951,450	0
2.	Cost of short-term investments acquired		
3.	Accrual of discount	38,840	60,094
4.	Unrealized valuation increase (decrease)	0	0
5.	Total gain (loss) on disposals	1,514	0
6.	Deduct consideration received on disposals	3,991,804	7,000,000
7.	Deduct amortization of premium	0	0
8.	Total foreign exchange change in book/adjusted carrying value	0	0
9.	Deduct current year's other than temporary impairment recognized		
10.	Book/adjusted carrying value at end of current period (Lines 1+2+3+4+5-6-7+8-9)	0	3,951,450
11.	Deduct total nonadmitted amounts	0	0
12.	Statement value at end of current period (Line 10 minus Line 11)	0	3,951,450

# Schedule DB - Part A - Verification - Options, Caps, Floors, Collars, Swaps and Forwards NONE

Schedule DB - Part B - Verification - Futures Contracts

# NONE

Schedule DB - Part C - Section 1 - Replication (Synthetic Asset) Transactions (RSATs) Open **NONE** 

Schedule DB-Part C-Section 2-Reconciliation of Replication (Synthetic Asset) Transactions Open **NONE** 

Schedule DB - Verification - Book/Adjusted Carrying Value, Fair Value and Potential Exposure of Derivatives

NONE

# **SCHEDULE E - PART 2 - VERIFICATION**

(Cash Equivalents)

	(Odon Equivalents)	1	2
		Year To Date	Prior Year Ended December 31
1.	Book/adjusted carrying value, December 31 of prior year	8,275,485	3, 167, 562
2.	Cost of cash equivalents acquired		
3.	Accrual of discount		
4.	Unrealized valuation increase (decrease)	0	0
5.	Total gain (loss) on disposals	0	0
6.	Deduct consideration received on disposals	19,003,190	150,439,030
7.	Deduct amortization of premium	0	0
8.	Total foreign exchange change in book/adjusted carrying value	0	0
9.	Deduct current year's other than temporary impairment recognized	0	0
10.	Book/adjusted carrying value at end of current period (Lines 1+2+3+4+5-6-7+8-9)	4,275,414	8,275,485
11.	Deduct total nonadmitted amounts	0	0
12.	Statement value at end of current period (Line 10 minus Line 11)	4,275,414	8,275,485

# Schedule A - Part 2 - Real Estate Acquired and Additions Made **NONE**

Schedule A - Part 3 - Real Estate Disposed **N O N E** 

Schedule B - Part 2 - Mortgage Loans Acquired and Additions Made **NONE** 

Schedule B - Part 3 - Mortgage Loans Disposed, Transferred or Repaid

NONE

Schedule BA - Part 2 - Other Long-Term Invested Assets Acquired and Additions Made NONE

Schedule BA - Part 3 - Other Long-Term Invested Assets Disposed, Transferred or Repaid **NONE** 

# **SCHEDULE D - PART 3**

Show All Long-Term Bonds and Stock A	

			Show All L	ong-Term Bonds and Stock Acquired During the Current Quarter.					
1	2	3	4	5	6	7	8	9	10
									NAIC
									Designation,
									NAIC
									Designation
									Modifier
									and
									SVO
					Number of			Paid for Accrued	Admini-
CUSIP			Date		Shares of			Interest and	strative
Identification	Description	Foreign	Acquired	Name of Vendor	Stock	Actual Cost	Par Value	Dividends	Symbol
3136BN-L7-9 FNR 2022-54 DB - (	CMO/PMBS		01/01/2023	D. A. DAVIDSON & CO		(600)	0	0	1.A
3137FB-TA-4 FHMS K-728 A2 - C	MBS		02/01/2023	HILLTOP SECURITIES INC			0	0	1.A
				U.S. Bank		(681)	0	0	1.A
	MBS		02/01/2023	U.S. Bank		681	0	0	1.A
09099999999999999999999999999999999999	s - U.S. Special Revenues					1,361	0	0	XXX
12650U-AU-5 CSMLT 2015-3 2A7			02/01/2023	U.S. Bank		4,206	0	0	1.A FE
11099999999. Subtotal - Bonds	s - Industrial and Miscellaneous (Unaffiliated)					4,206	0	0	XXX
2509999997. Total - Bonds - I						5,567	0	0	XXX
2509999998. Total - Bonds - I	Part 5					XXX	XXX	XXX	XXX
25099999999. Total - Bonds						5,567	0	0	XXX
4509999997. Total - Preferred						0	XXX	0	XXX
4509999998. Total - Preferred	d Stocks - Part 5					XXX	XXX	XXX	XXX
450999999999999999999999999999999999999						0	XXX	0	XXX
5989999997. Total - Commor	Stocks - Part 3					0	XXX	0	XXX
5989999998. Total - Commor						XXX	XXX	XXX	XXX
59899999999999999999999999999999999999						0	XXX	0	XXX
59999999999999999999999999999999999999	d and Common Stocks					0	XXX	0	XXX
6009999999 - Totals						5.567	XXX	0	XXX

## **SCHEDULE D - PART 4**

Chau All Lang Tarm Danda and Ctaal Cald	. Redeemed or Otherwise Disposed of During the Current Quarter

					Show All Lo	ng-Term Bo	onds and Sto	ck Sold, Red	deemed or C	Otherwise	Disposed of	of During th	he Current	Quarter							
1	2	3	4	5	6	7	8	9	10	C	nange In Boo	ok/Adjusted	Carrying Va	lue	16	17	18	19	20	21	22
										11	12	13	14	15							NAIC
																					Desig-
																					nation,
																					NAIC
													Total	Total							Desig-
												Current	Change in	Foreign					Bond		nation
												Year's	Book/	Exchange	Book/				Interest/		Modifier
									Prior Year		Current	Other Than	Adjusted	Change in	Adjusted	Foreign			Stock	Stated	and
									Book/	Unrealized		Temporary	Carrying	Book	Carrying	Exchange			Dividends	Con-	SVO
CUSIP					Number of				Adjusted	Valuation	(Amor-	Impairment	t Value	/Adjusted	Value at	Gain	Gain	Total Gain	Received	tractual	Admini-
Ident-		For-	Disposal	Name	Shares of	Consid-		Actual	Carrying	Increase/	tization)/	Recog-	(11 + 12 -	Carrying	Disposal	(Loss) on	(Loss) on	(Loss) on	During	Maturity	
ification	Description	eign		of Purchaser	Stock	eration	Par Value	Cost	Value	(Decrease)		nized	13)	Value	Date	Disposal	Disposal	Disposal	Year	Date	Symbol
38383Y-4M-1	GNR 2022-179 MV - CMO/RMBS		. 03/01/2023 .	Paydown		13,415	13,415	13,886	(5,389)	0	794	0	794	0	13,865	0	(450)	(450)	(3,799)	. 08/20/2033 .	. 1.A
912828-W7-1	UNITED STATES TREASURY		. 03/29/2023 .	CITIGROUP GLOBAL MARKETS		2. 441. 105	2.500.000	0 440 070	2.419.366	0	15.310		15.310		2.434.676	0	6.429	6.429	00 447	00/04/0004	
912828-11/-1	UNITED STATES THEASURY		. 03/29/2023 .	NOMURA SECURITIES INTL	•••••	2,441,105	2,500,000	2,413,973	2,419,366	0	15,310	0	15,310	0	2,434,676	0	6,429		26,417	. 03/31/2024 .	. 1.A
91282C-EU-1	UNITED STATES TREASURY		. 03/29/2023 .	FIXED I		390 . 124	400.000	395.783	396.322	0	351	0	351	0	396.673	0	(6.549)	(6.549)	3,317	. 06/15/2025 .	. 1.A FE
				NOMURA SECURITIES INTL.,			,	,									, , , , ,	, , , , ,	.,.		
	UNITED STATES TREASURY		. 03/29/2023 .	FIXED I		280,511	300,000	287,040	287,408	0	271	0	271	0	287,679	0	(7, 168)	(7, 168)	5, 105	. 08/15/2032 .	_
	99. Subtotal - Bonds - U.S. Governme	ents				3, 125, 155	3,213,415	3,110,682	3,097,708	0	16,725	0	16,725	0	3, 132, 893	0	(7,739)	(7,739)	31,040	XXX	XXX
			. 03/01/2023 .	Paydown		3,046	3,046	2,959	2,978	0	1	0	1	0	2,979	0	67	67	10	. 08/01/2031 .	. 1.A
	FH G18663 - RMBS		. 03/01/2023 .	Paydown		2,830	2,830	2,919	2,915	0	(1)	0	(1)	0	2,914	0	(84)	(84)	13	. 10/01/2032 .	. 1.A
3128P8-FQ-9	FH C91975 - RMBS		. 03/30/2023 .	Various		974,901	1,054,756	976,968	976,791	0	766	0	766	0	977,557	0	(2,656)	(2,656)	7,849	. 02/01/2038 .	. 1.A
3132AA-F9-0	FH ZS9192 - RMBS		. 03/30/2023 .	Various		952,323	1,021,200	954,024	953,905	0	892	0	892	0	954,797	0	(2,474)	(2,474)	7,620	. 01/01/2036 .	. 1.A
3132D6-C3-2	FH SB8190 - RMBS		. 03/30/2023 .	Various		957,501	964,097	937 , 886	938 , 152	0	570	0	570	0	938,722	0	18,779	18,779	10,825	. 11/01/2037 .	. 1.A
3132DN-4L-4	FH SD1727 - RMBS		. 03/30/2023 .	Various		983,684	990,435	956,699	956,888	0	706	0	706	0	957,593	0	26,091	26,091	12,602	. 11/01/2052 .	. 1.A
3132DN-ZC-0	FH SD1639 - RMBS		. 03/30/2023 .	Various		944, 163	991,538	906,018	906,565	0		0	1,394	0	907,959	0	36,204	36,204	10,031	. 09/01/2052 .	. 1.A
3132DW-DS-9	FH SD8213 - RMBS		. 03/30/2023 .	Various		864,631	967,584	820 , 178	821, 147	0	2,031	0	2,031	0	823, 178	0	41,452	41,452	7,384	. 05/01/2052 .	. 1.A
3132DW-ER-0	FH SD8244 - RMBS		. 03/01/2023 .	Paydown		2,970	2,970	2,951	2,951	0	0	0	0	0	2,951	0	19	19	20	. 09/01/2052 .	. 1.A
3132XT-PU-6	FH Q51334 - RMBS		. 03/01/2023 .	Paydown		1,894	1,894	1,970	2,040	0	0	0	0	0	2,040	0	(146)	(146)	15	. 10/01/2047 .	. 1.A
3132XU-KF-1	FH Q52093 - HMBS		. 03/01/2023 .	Paydown			2,172	2,244	2,277	0	(1)	0	0	0	2,277	0	(105)	(105)	12	. 11/01/2047 .	. 1.A
3136AQ-AQ-3 3136B2-6W-7	FNR 2015-72 PD - CMO/RMBS		. 03/01/2023 .	Paydown	•••••	947.500	14,747	14,814	14,726	0	3.417		(1)	0	14,725	0	20.297	22	75 9.279	. 10/25/2043 . . 08/25/2030 .	. I.A
3136BN-L7-9	FNR 2022-54 DB - CM0/RMBS		. 03/30/2023 .	D. A. DAVIDSON & CO		947,500	0	922, 149	(13)	0	13		13		0		20,297	20,297	9,2/9	. 08/25/2030 . . 08/25/2037 .	. I.A
3137BH-XJ-1	FHMS K-045 A2 - CMBS		. 01/01/2023 .	Pavdown		762	762	751	752						752		10	10		. 06/25/2037 . . 01/25/2025 .	1.A
3137BH-XJ-1	FHMS K-045 A2 - CMBS		. 03/01/2023 .	Paydown		1,665		1,640					1				21	21	11	. 01/25/2025 .	. 1.A FE
3137BK-GK-0	FHMS K-1501 A3 - CMBS		. 03/30/2023 .	BARCLAYS CAPITAL INC			815.000	743.051			2.139		2, 139	0	746 .394	0	26.964	26.964	7,313	. 04/25/2020 .	1 4
3137BL-MZ-8	FHMS K-049 A2 - CMBS		. 01/01/2023 .	DANGERTO ONI TIAE TNO			015,000	0			(2, 198)	0	(2, 198)	0	0	0	0	n	(2,508)	. 07/25/2005 .	1 4
3137BM-TX-4	FHMS K-052 A2 - CMBS		. 01/01/2023 .			0	0	0		0	(2, 150)	0	(2, 160)	0	0	0	0	0	(2,626)	. 11/25/2025 .	1 A
3137FB-TA-4	FHMS K-728 A2 - CMBS		. 03/01/2023 .	Pavdown		4.338	4.338	4.211	4.221	0	7	0	7	0	4.228	0	110	110	23	. 08/25/2024 .	1.A
				INDUSTRIAL & COMM BNK OF		,***	.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,	*						,,						
3137FC-JK-1	FHMS K-070 A2 - CMBS		. 03/30/2023 .	CHINA		952,500	1,000,000	936,250	1,617	0	2,942	0	2,942	0	940,809	0	11,691	11,691		. 11/25/2027 .	. 1.A
	FHMS K-072 A2 - CMBS		. 03/30/2023 .	HILLTOP SECURITIES INC		960,625	1,000,000	941,406		0	2,620	0	2,620	0	945,462	0	15, 163	15, 163	8,801	. 12/25/2027 .	. 1.A
3137FL-6P-4	FHMS K-089 A2 - CMBS		. 03/30/2023 .	HILLTOP SECURITIES INC		669,813	700,000	689,369	689,240	0	333	0	333	0	689,573	0	(19,760)	(19,760)	6,374	. 01/25/2029 .	. 1.A
3137H8-U9-0	FH-K148-A2 - CMBS		. 01/01/2023 .			0	0	0		0	(1,297)	0	(1,297)	0	0	0	0	0	(2,917)	. 07/25/2032 .	. 1.A
3137H8-U9-0	FHMS K-148 A2 - CMBS		. 03/30/2023 .	HILLTOP SECURITIES INC		935,938	1,000,000	890 , 156	0	0	3,599	0	3,599	0	893,755	0	42, 183	42, 183	11,861	. 07/25/2032 .	. 1.A FE
3137H9-C9-8	FHMS K-150 A2 - CMBS		. 03/30/2023 .	HILLTOP SECURITIES INC		948,906	1,000,000	943,438	943,759	0	1, 114	0	1, 114	0	944,872	0	4,034	4,034	9,481	. 09/25/2032 .	. 1.A FE
3138AX-XQ-9	FN AJ6086 - RMBS		. 03/01/2023 .	Paydown		4,857	4,857	5,016	4,936	0	(2)	0	(2)	0	4,934	0	(77)	(77)	24	. 12/01/2026 .	. 1.A
3138XD-TR-1	FN AV2359 - RMBS		. 03/01/2023 .	Paydown		2,460	2,460	2,600		0	(1)	0	(1)	0	2,652	0	(192)	(192)	17	. 01/01/2044 .	. 1.A
3140FV-TZ-9	FN BE9567 - RMBS		. 03/01/2023 .	Paydown		1,637		1,681		0	0	0	0	0	1,699	0	(62)	(62)	12	. 04/01/2047 .	
3140GQ-4C-7	FN BH2618 - RMBS		. 03/30/2023 . . 03/01/2023 .	Various		938,495	1,005,626	902,235	902, 138	0	472	0		0	902,610	0	35,885	35,885		. 08/01/2047 .	.   I.A
3140J9-AM-3 3140LD-MJ-5	FN BM4511 - HMBS		. 03/01/2023 .	Paydown	•	3, 116	3,116	3,186 841.250		0	5.663	0	(1)	0		······	(74)	(74)	26	. 07/01/2033 . . 11/01/2028 .	1.A
3140LD-MJ-5	FN CA2352 - RMBS		. 03/30/2023 .	Pavdown				3,611									(1, 169)	(1, 169)		. 11/01/2028 . . 09/01/2048 .	1 A
3140Q9-13-2 3140QK-VB-1	FN CRO609 - RMRS		. 03/01/2023 .	Paydown		1.845		1,719	1.719		(1)		(1)		1.719				29	. 09/01/2048 . . 05/01/2051 .	1.A
31410L-FY-3	FN 890383 - RMRS		. 03/01/2023 .	Paydown		1,845				0	o	o		n	1,719	n	(89)	(89)	10	. 05/01/2051 . . 01/01/2042 .	1.Λ
31418D-3Y-6	FN MAAA1A = BMBS		. 03/01/2023 .	Various	•••••		1,055,530				1.424		1.424	^	895.250		11.999	11.999	6.689	. 01/01/2042 . . 09/01/2051 .	Ι Δ
	FN MA4814 - RMBS		. 03/30/2023 .	Various		907,249	979,908	978,683	978.669	0		o		n	978.618	n	4,790	4,790	12,248	. 12/01/2037 .	1.Λ
	SLST 2021-1 A1D - CMO/RMBS		. 03/30/2023 .	Pavdown	•••••	7.328			7.512	n	(1)	n	(1)	n		0			25	. 12/01/2037 . . 04/25/2061 .	1 A

# **SCHEDULE D - PART 4**

					Show All Lo	ng-Term Bo	onds and Sto	ck Sold, Red	deemed or C	Otherwise L	Disposed (	of During th	ne Current	Quarter							
1	2	3	4	5	6	7	8	9	10	Ch	ange In Bo	ok/Adjusted	Carrying Va	lue	16	17	18	19	20	21	22
										11	12	13	14	15							NAIC
																					Desig-
																					nation,
																					NAIC
													Total	Total							Desig-
												Current		Foreign					Bond		nation
												Current	Change in		Book/				Interest/		Modifier
									Prior Year		0	Year's	Book/	Exchange		Faraian			Stock	Ctotod	
												Other Than	Adjusted	Change in	Adjusted	Foreign	Daaliaad			Stated Con-	and SVO
CUSIP					Ni				Book/	Unrealized	Year's	Temporary	Carrying	Book	Carrying	Exchange	Realized	T-4-1 O-1-	Dividends		
			Diamaga	Na	Number of	0		A =4=1	Adjusted	Valuation	(Amor-	Impairment	Value	/Adjusted	Value at	Gain	Gain	Total Gain	Received	tractual	Admini-
Ident-	Description	For-		Name	Shares of	Consid-	Deallaline	Actual	Carrying	Increase/	tization)/	Recog-	(11 + 12 -	Carrying	Disposal	(Loss) on	(Loss) on	(Loss) on	During	Maturity	strative
ification	Description	eign		of Purchaser	Stock	eration	Par Value	Cost	Value	(Decrease)	Accretion	nized	13)	Value	Date	Disposal	Disposal	Disposal	Year	Date	Symbol
	LOUISIANA LOC GOVT ENVIRONMENTAL FACS &		. 02/01/2023 .	Paydown		12,454	0	0	(6)	0	3	0	3	0	(3)	0	12,456	12,456	(178)	. 08/01/2028 .	1.A FE
	99. Subtotal - Bonds - U.S. Special Re	evenu		,	1	15,615,971	16,606,073	15,294,528	10,877,576	0	24,494	0	24,494	0	15,335,083	0	280,888	280,888	141,244	XXX	XXX
00842V-AC-7	ABMT 2016-3 A3 - CMO/RMBS		. 03/01/2023 .	Paydown		1,076	1,076	1,096		0	0	0	0	0	1, 101	0	(25)	(25)	6	. 08/27/2046 .	1.A
03465D-AA-1	AOMT 2021-2 A1 - CMO/RMBS		. 03/01/2023 .	Paydown		3, 120		3 , 124	3, 124	0	0	0	0	0		0	(4)	(4)	5	. 04/25/2066 .	1.A
037680-AA-3	AEPWV 1113 A1 - ABS		. 02/01/2023 .	Paydown		17,932	17,932	17 , 838	17,929	0	3	0	3	0	17,932	0	0	0	180	. 02/01/2024 .	1.A FE
06540W-BA-0	BANK 2019-BNK19 A1 - CMBS		. 03/01/2023 .	Paydown		13, 120	13, 120	13,120	13,112	0	0	0	0	0	13, 112	0	8	8	52	. 08/17/2061 .	1.A
12568P-AA-1	CIM 2020-J2 A1 - CMO/RMBS		. 03/01/2023 .	Paydown		1,229	1,229	1,244		0	0	0	0	0	1,244	0	(15)	(15)	5	. 01/25/2051 .	1.A
12650U-AU-5	CSMLT 2015-3 2A7 - CMO/RMBS		. 03/01/2023 .	Paydown		12,950	12,950	12,055	(4,088)	0	(116)		(116)	0	12,071	0	879	879	(809)	. 10/25/2030 .	1.A FE
252722-AA-1	DROT 191 A - RMBS		. 03/20/2023 .	Paydown		20,731	20,731	21,262	21,203	0	(5)	0	(5)	0	21, 198	0	(467)	(467)	98	. 02/20/2032 .	1.A FE
33851M-AA-0	FSMT 2021-91NV A1 - CMO/RMBS		. 03/01/2023 .	Paydown		3,808	3,808	3,933	3,925	0	(1)	0	(1)	0		0	(117)	(117)	17	. 10/25/2041 .	1.A
44933L-AC-7	HART 2021-A A3 - ABS		. 03/15/2023 .	Paydown		20,722	20,722	20,720	20,721	0	0	0	0	0	20,721	0	1	1	13	. 09/15/2025 .	1.A FE
46654D-AE-3	JPMMT 211NV4 A2A - CMO/RMBS		. 03/25/2023 .	Paydown		2,232		2,279	2,278	0	0	0	0	0	2,277	0	(46)	(46)	10	. 01/25/2052 .	1.A
69363P-AA-8	PSNH 2018-1 A1 - ABS		. 02/01/2023 .	Paydown		19,691	19,691	19,690	19,691	0	0	0	0	0	19,691	0	0	0	305	. 02/01/2026 .	1.A FE
81744N-AA-8	SEMT 2012-6 A1 - CMO/RMBS		. 03/01/2023 .	Paydown		1,076	1,076	1,090	1,086	0	0	0	0	0	1,086	0	(10)	(10)	4	. 12/26/2042 .	1.A FM
81745M-AA-9	SEMT 2013-2 A - CMO/RMBS		. 03/01/2023 .	Paydown		711	711	641	606	0	1	0	1	0	607	0	104	104	3	. 02/25/2043 .	1.A
81745R-AA-8	SEMT 2013-3 A1 - CMO/RMBS		. 03/01/2023 .	Paydown		1,404	1,404	1,372	1,349	0	0	0	0	0	1,349	0	55	55	5	. 03/25/2043 .	1.A
81748K-AA-0	SEMT 2020-2 A1 - CMO/RMBS		. 03/01/2023 .	Paydown		4, 142	4, 142	4,219	4,429	0	(19)	0	(19)	0	4,410	0	(269)	(269)	18	. 03/25/2050 .	1.A
88315L-AS-7	TMCL 2021-3 A - ABS	C	. 03/20/2023 .	Paydown		5,000	5,000	4,999	4,999	0	0	0	0	0	4,999	0	1	1	16	. 08/20/2046 .	1.F FE
89179Y-AR-4			. 03/25/2023 .	Paydown		8,424	8,424		8,527	0	(5)		(5)	0	8,522	0	(99)	(99)	29	. 11/25/2061 .	1.A
	STEAM 2021-1 A - ABS	J	. 03/28/2023 .	Paydown		2,682	2,682	2,715	2,708	0	(1)		(1)	0	2,707	0	(26)	(26)	10	. 02/28/2051 .	1.F FE
	99. Subtotal - Bonds - Industrial and M	liscel	aneous (Un	affiliated)		140,048	140,048	139,960	123,945	0	(143)	0	(143)	0	140,078	0	(30)	(30)	(33)	XXX	XXX
	97. Total - Bonds - Part 4					18,881,174	19,959,536	18,545,170	14,099,230	0	41,077	0	41,077	0	18,608,054	0	273, 120	273, 120	172,251	XXX	XXX
	98. Total - Bonds - Part 5					XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX
	99. Total - Bonds					18,881,174	19,959,536	18,545,170	14,099,230	0	41,077	0	41,077	0	18,608,054	0	273, 120	273, 120	172,251	XXX	XXX
	97. Total - Preferred Stocks - Part 4					0	XXX	0	•	0	0		0	0	0	0	0	0	0	XXX	XXX
	98. Total - Preferred Stocks - Part 5					XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX
	99. Total - Preferred Stocks					0	XXX	0	0	0	0	0	0	0	0	0	0	0	0	XXX	XXX
	97. Total - Common Stocks - Part 4					0	XXX	0	•	0	0		0	0	0	0	0	0	0	XXX	XXX
	98. Total - Common Stocks - Part 5					XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX
	99. Total - Common Stocks					0	XXX	0	0	0	0	0	0	0	0	0	0	0	0	XXX	XXX
	99. Total - Preferred and Common Sto	ocks				0	XXX	0	0	0	0	-	0	0	0	0	0	0	0	XXX	XXX
600999999	99 - Totals					18,881,174	XXX	18,545,170	14,099,230	0	41,077	0	41,077	0	18,608,054	0	273, 120	273, 120	172,251	XXX	XXX

# Schedule DB - Part A - Section 1 - Options, Caps, Floors, Collars, Swaps and Forwards Open NONE

Schedule DB - Part B - Section 1 - Futures Contracts Open NONE

Schedule DB - Part B - Section 1B - Brokers with whom cash deposits have been made **NONE** 

Schedule DB - Part D - Section 1 - Counterparty Exposure for Derivative Instruments Open **NONE** 

Schedule DB - Part D-Section 2 - Collateral for Derivative Instruments Open - Pledged By

NONE

Schedule DB - Part D-Section 2 - Collateral for Derivative Instruments Open - Pledged To NONE

Schedule DB - Part E - Derivatives Hedging Variable Annuity Guarantees **NONE** 

Schedule DL - Part 1 - Reinvested Collateral Assets Owned NONE

Schedule DL - Part 2 - Reinvested Collateral Assets Owned NONE

# **SCHEDULE E - PART 1 - CASH**

Month	Fnd	Depository	Ralances
IVIOLITI	LIIU		Dalalices

2	3	4	5				9
					uring Current Quar		
				6	7	8	
	D-4f						
0-4-				F1 ( NA ()	0	T0 1 - 1 NA 10	*
	0.000	0	0	300,000	300,000	300,000	XXX.
	0.000			56, 189, 594	45,854,692	119,242,243	xxx.
	0 000						~~~
	0.008			3,922,410	3,890,594	3,857,564	XXX.
					(0.40=)	(0.40=)	
XXX	XXX	-		, -	(-, -,	(-, - ,	XXX
XXX	XXX	0	0	56,686,592	46,368,861	110,520,335	XXX
XXX	XXX	0	0	0	0	0	XXX
XXX	XXX	0	0	0	0	0	XXX
XXX	XXX	0	0	56,686,592	46,368,861	110,520,335	XXX
XXX	XXX	XXX	XXX	0	0	0	XXX
		Λ	Λ	56 686 502	46 368 861	110 520 335	XXX
	Code	Rate of   Interest	Amount of   Interest Received   During Current   Quarter   Quart	Amount of Interest Received During Current Quarter   Statement Date	Amount of Interest Received During Current Quarter	Amount of Interest Received During Current Quarter   Statement Date   First Month   Second Month	Amount of Interest Received During Current Quarter

# **SCHEDULE E - PART 2 - CASH EQUIVALENTS**

Show Investments Owned End of Current Quarter

		Show Investments O	wnea Ena of Curren	ι Quaπer				
1	2	3	4	5	6	7 Book/Adjusted	8 Amount of Interest	9 Amount Received
CUSIP	Description	Code	Date Acquired	Rate of Interest	Maturity Date	Carrying Value	Due and Accrued	During Year
0109999999. Total - U.S. Government Bonds						0	0	0
0309999999. Total - All Other Government Bonds						0	0	0
0509999999. Total - U.S. States, Territories and Posse	essions Bonds					0	0	0
0709999999. Total - U.S. Political Subdivisions Bonds						0	0	0
0909999999. Total - U.S. Special Revenues Bonds						0	0	0
1109999999. Total - Industrial and Miscellaneous (Una	ffiliated) Bonds					0	0	0
1309999999. Total - Hybrid Securities	•					0	0	0
1509999999. Total - Parent, Subsidiaries and Affiliates	Bonds					0	0	0
1909999999. Subtotal - Unaffiliated Bank Loans						0	0	0
2419999999. Total - Issuer Obligations						0	0	0
2429999999. Total - Residential Mortgage-Backed Sec	curities					0	0	0
2439999999. Total - Commercial Mortgage-Backed Se						0	0	0
2449999999. Total - Other Loan-Backed and Structure						0	0	0
2459999999. Total - SVO Identified Funds						0	0	0
2469999999. Total - Affiliated Bank Loans						0	0	-
2479999999. Total - Unaffiliated Bank Loans						0	0	0
2509999999. Total Bonds						0	0	0
31846V-54-2 FIRST AMER: TRS OBG Z			03/02/2023	4.660			387	1.032
38145C-75-2 GOLDMAN:FS TS CM			03/01/2023	3.870		520,516	1,651	4,314
8209999999. Subtotal - Exempt Money Market Mutual	Funds - as Identified by the SVO					621.565	2.038	5,347
31846V-56-7 FIRST AMER:GVT OBLG Z			03/31/2023	4.610				
8309999999. Subtotal - All Other Money Market Mutual	l Funds			<u> </u>		3.653.850	21.297	1.474
						5,555,555	=-,==-	.,
								•••••
								•••••
960000000 Total Cook Faviral anto						4 075 444	20.005	
8609999999 - Total Cash Equivalents						4,275,414	23,335	6,821